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INFORMED CONSENT IN THE PRESCRIPTION
DRUG CONTEXT: THE SPECIAL CASE
Gerald F. Tietz*
Medical patients rarely bring suit against prescribing physicians on an
informed consent theory in the context of prescription drug therapy.1 By
contrast, patients frequently file suit against their physicians for failure to
obtain an informed consent to surgery and other bodily invasive medical
treatments.2 Yet physicians employ prescription drugs far more frequently
than any other therapy,3 and prescription drugs result in a proportionally
larger number of side effects and related injuries. 4 Moreover, physicians
appear to disclose to patients little, if any, information about the risks of
serious side effects or about alternative treatments.5 One would therefore
expect to see many more prescription drug claims litigated under the theory
of lack of informed consent.6 The fact that so few prescription drug claims
* Associate Professor of Law, Temple University School of Law.
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drafts of this article: Professors Anthony Bocchino, Diane Maleson, Frank McClellan, Henry
Richardson, David Sonenshein, and Sidney Willig. The author also wishes to thank Susan McCluskey,
a second-year Temple Law Student, for invaluable research and assistance with footnotes and Sanford
Pitler, Executive Articles Editor, Washington Law Review, for exceptional editorial efforts.
1. The number of reported appellate decisions, including cases involving prescription drug
injections given by the treating physician and therefore involving no written prescription, is probably
less than 20. See infra notes 8-9.
2. See generally A. RosoFF, INFORMED CONsENT-A GUIDE FOR HEALTH CARE PROVIDERS 313-447
(1981).
3. See infra notes 96-101 and accompanying text.
4. See infra notes 96-152 and accompanying text.
5. See, e.g., R. MENDELSOHN, MALE PRACTICE: How DocroRs MANIPULATE WOMEN 36-37 (1982)
(arguing that oral contraceptives have been prescribed as if they were no more hazardous than chewing
gum). Not only are physicians quick to prescribe drugs, they do so without providing their patients with
much, if any, information about potentially dangerous side effects. One physician argued in his own
defense that while he agreed that patients should be told about side effects, physicians should not give
patients so much information as to scare them. "In other words, it is all right to tell a [patient] that a drug
might make her nauseous, but . . . don't tell her . . . that it might also cause convulsions, heart
failure, or anaphylactic shock!" Id. at 59. Other commentators have found that physicians believe that
patients are too ignorant to make their own medical decisions and increased disclosure only heightens
patients' fears. See L KATz, THE SILENT WORLD OF DOcTOR AND PATIENT 83 (1984); see also Boyer v.
Smith, No. 80-12190-6, slip op. at 2 (C.P. Bucks County, Pa., Jan. 28, 1985), aff'd, 497 A.2d 646 (Pa.
Super. 1985); 2 PRESIDENT'S COMMISSION FOR THE STUDY OF ETHICAL PROBLEMS IN MEDICINE AND
BIOMEDICAL AND BEHAVIORAL RESEARCH, MAKING HEALTH CARE DECISIONS [hereinafter cited as 2
PRESIDErr's COMMISSION] 167 table 5-4 (1982) (only 23% of physicians polled think informed consent
means that the patient understands treatment risks); infra notes 91-132, 162-211 and accompanying
text.
6. The dearth of appellate decisions might be explained in part by the fact that, although in
prescription drug cases prescribing physicians are often named as defendants, the primary target is
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are brought might suggest that patients' rights, normally protected by the
doctrine of informed consent, are not adequately protected when patients
undergo prescription drug therapy.
To understand the current law of informed consent in the area of pre-
scription drugs, one must look to the separate and divergent development
of the law of informed consent generally. Currently, courts adopt one of two
models of informed consent: the medical-community model and the pa-
tient-oriented model (objective-patient model). 7 The medical-community
model, adopted by a majority of jurisdictions, determines the existence and
scope of a physician's duty to inform by the standard of practice of
physicians in the medical community.8 A significant number of jurisdic-
tions, however, determine the existence and scope of the physician's duty to
inform based on the information a reasonable patient would find material in
deciding whether or not to undergo the proposed therapy. 9 However, both
models employ a reasonable patient standard for determining proximate
cause: that is, whether the patient would have consented to the therapy had
the physician adequately disclosed pertinent information. 10
usually the drug manufacturer. See infra notes 109, 130. Very often the claim against the prescribing
physician is resolved before trial. See, e.g., Lindsay v. Ortho Pharmaceutical Corp., 637 F.2d 87 (2d
Cir. 1980); Magee v. Wyeth Labs., 214 Cal. App. 2d 340, 29 Cal. Rptr. 322 (1963); Formella v. Ciba-
Giegy Corp., 100 Mich. App. 649, 300 N.W.2d 356 (1980); McKee v. Moore, 648 P.2d 21 (Okla.
1982); Gravis v. Parke-Davis & Co., 502 S.W.2d 863 (Tex. Civ. App. 1973); see also Ortiz v. Allergan
Pharmaceuticals, 489 S.W.2d 135 (Tex. Civ. App. 1972) (claims against physician settled during trial).
Despite the large number of injuries and deaths associated with the use of prescription drugs, attorneys
do not regard informed consent claims in the prescription drug context as viable cases because of the
heavy burden placed on plaintiffs. This heavy burden results from the judiciary's tendency to apply a
medical-community standard to prescription drug claims. See infra notes 8, 28.
7. See infra notes 24-46 and accompanying text.
8. See, e.g., Watkins v. United States, 482 F. Supp. 1006 (M.D. Tenn. 1980); Finley v. United
States, 314 F. Supp. 905 (N.D. Ohio 1970); Carmichael v. Reitz, 17 Cal. App. 3d 958,95 Cal. Rptr. 381
(1971); Calabrese v. Trenton State College, 162 N.J. Super. 145, 392 A.2d 600 (1978); Koury v. Folio,
272 N.C. 366, 158 S.E.2d 548 (1968); Boyer v. Smith, 497 A.2d 646 (Pa Super. 1985); Malloy v.
Shanahan, 280 Pa. Super. 440,421 A.2d 803 (1980); Kaiser v. Suburban Transp. Sys., 65 Wn. 2d 461,
398 P.2d 14 (1965); Trogun v. Fruchtman, 58 Wis. 2d 596, 207 N.W.2d 297 (1973); see also infra notes
27-32 and accompanying text.
9. See Canterbury v. Spence, 464 F.2d 772 (D.C. Cir. 1972), cert. denied, 409 U.S. 1064 (1972)
(the leading case establishing an objective-patient standard of disclosure); see also Cobbs v. Grant, 8
Cal. 3d 229, 104 Cal. Rptr. 505, 502 P.2d 1 (1972); Hamilton v. Hardy, 37 Colo. App. 375, 549 P.2d
1099 (1976); Harnish v. Children's Hosp. Medical Center, 387 Mass. 152, 439 N.E.2d 240 (1982);
Cooper v. Roberts, 220 Pa. Super. 260, 286 A.2d 647 (1971); Holt v. Nelson, 11 Wn. App. 230,523 P.2d
211 (1974); Scaria v. St. Paul Fire & Marine Ins., 68 Wis. 2d 1, 227 N.W.2d 647 (1975).
10. Some courts have recognized the unique perspective of every patient, and for that reason have
rejected the objective-patient standard in favor of a subjective-patient approach. See McPherson v.
Ellis, 305 N.C. 266,287 S.E.2d 892 (1982); Scott v. Bradford, 606 P.2d 554 (Okla. 1979). With respect
to the proximate cause element, Scott abandoned the objective, reasonable-patient standard adopted in
Canterbury in favor of a subjective standard. In Scott, plaintiff had a hysterectomy and later suffered
incontinence caused by a vesico-vaginal fistula. Scott, 606 P.2d at 556. Plaintiff claimed that her doctor
had not informed her of this risk, and she maintained that had she been fully informed of all risks she
368
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In the prescription drug context, however, courts have almost universally
applied the medical-community standard to determine the existence and
scope of the physician's duty to inform and have thereby ignored patients'
rights.' This extreme judicial deference to medical autonomy in the
prescription drug context largely results from the courts' failure to examine
the unique factors present in prescription drug therapy. 12
Evaluation of the general doctrine of informed consent is the starting
point for determining whether, and how, the doctrine might apply to
prescription drug therapy. This article demonstrates that, unlike the deci-
sion to undergo surgery (the more typical informed consent situation), 13 the
process of prescribing drugs contains numerous considerations, many of
which are inherent in and unique to prescription drug therapy. The presence
of these considerations dictates that courts accord even greater significance
to the need for patient participation in prescription drug therapy than that
accorded in the more typical consent to surgery situation. 14 Moreover, in
light of the many unique considerations involved, courts need to examine
their ready deference to physicians' autonomy, which results in total
exclusion of patient participation15 and the abrogation of patients' rights of
self-determination and bodily integrity. 16 This article argues that when the
would have refused the surgery. Id. The court held that the physician's duty is to make a full disclosure
of all material risks incident to the treatment, the materiality of which is to be determined by the finder
of fact. Id. at 558. This is consistent with the Canterbury standard, but the Scott standard differs sharply
with regard to causation. In Scott, the relevant causation inquiry is whether the particular patient, and
not the reasonable patient, would have consented to the treatment had she been fully informed. Id. at
559.
11. See supra note 8; infra notes 27-32 and accompanying text. One exception to the adoption of
the medical-community standard in prescription drug cases can be found in Hamilton v. Hardy, 37
Colo. App. 375, 549 P.2d 1099 (1976), where the court applied an objective standard.
12. See infra notes 96-152 and accompanying text.
13. "Typical" is used in the sense that court decisions concerning informed consent far more often
involve surgery or bodily invasive exploratory testing than they do prescription drug situations.
14. See infra notes 96-152 and accompanying text.
15. See infra notes 64-69 and accompanying text.
16. One goal of informed consent is to allow patients to make decisions that affect their own bodies.
This goal can be met only when courts afford adequate protection to patients' rights of "self-
determination" and "bodily integrity." This premise was first stated in Schloendorff v. Society of N.Y.
Hosp., 211 N.Y. 125,105 N.E. 92, 93 (1914) ("[e]very human being of adult years and sound mind has a
right to determine what shall be done with his own body."). The doctrine of informed consent protects
the "physical integrity of the individual." Cooper v. Roberts, 220 Pa. Super. 260, 286 A.2d 647, 649
(1971). Beginning with the premise of self-determination, the common law recognized that individuals
are masters of their own bodies. Natanson v. Kline, 186 Kan. 383, 350 P.2d 1093, 1104 (1960).
Physicians could not substitute their own judgment for that of patients. Id. at 1104. Respect for the
patient's right of self-determination therefore demands that the courts, and not the medical profession,
set the standards by which physicians must obtain patients' consent prior to the commencement of
medical therapy. Canterbury v. Spence, 464 F.2d 772, 784 (D.C. Cir.), cert. denied, 409 U.S. 1064
(1972); see also infra notes 219-230 and accompanying text. In Scott v. Bradford, 606 P.2d 554, 559
(Okla. 1979), the court reemphasized the importance of allowing individual patients to make their own
decisions, regardless of the unreasonableness of the decision, else "a patient's right of self-determina-
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physician prescribes drug therapy, the only reasonable guarantee of a
patient's right of bodily integrity and self-determination is for courts to
apply a subjective, individual-patient standard of disclosure in conjunction
with a presumption of proximate cause. 17 Finally, the article proposes a
duty/disclosure scheme that alters the objective-patient model of informed
consent to accommodate the unique aspects of prescription drug therapy
and to give full force and effect to the patient's rights. 18
I. THE GENERAL LAW OF INFORMED CONSENT
The modern doctrine of informed consent finds its roots in the common
law doctrine that adults have a right to determine what will be done with
their bodies.' 9 To effect the common law rights of self-determination and
bodily integrity, modern courts have fashioned the doctrine of informed
consent. 20 On a state constitutional level, several jurisdictions have broadly
worded privacy protections, which may not require state action, and
therefore, lend themselves to interpretations embracing the rights of self-
determination, bodily integrity, and personal dignity.21
Courts developed the doctrine of informed consent to ensure the protec-
tion of patients' rights, and have fashioned alternate informed consent
models: the medical-community model and the objective or reasonable-
patient model ("objective-patient model"). Although the objective-patient
model provides, at least to some extent, protection for the patient's right to
tion is irrevocably lost" (emphasis in original). See infra notes 20, 22.
17. See infra notes 240-46 and accompanying text.
18. See infra notes 247-81 and accompanying text.
19. See supra note 16 and accompanying text.
20. True consent is an informed exercise of choice. To make this choice, the patient must have
knowledge of the factors involved, including the alternatives to, and the risks of, the proposed therapy.
Average patients have little or no understanding of medicine and must look to their physicians to provide
the information necessary for decisionmaking. Providing the patient the opportunity to make this
knowledgeable choice is the goal of informed consent and sets the parameters of the physician's duty to
disclose. See, e.g., Canterbury v. Spence, 464 F.2d 772, 780 (D.C. Cir.), cert. denied, 409 U.S. 1064
(1972); Lane v. Candura, 6 Mass. App. 377, 376 N.E.2d 1232, 1235-36 (1978) (court held that patient
had right to make her own decision concerning life-saving treatment, regardless whether the decision is
wise or unwise).
21. See, e.g., CAL. CONST. art. I, § I ("All people are by nature free and independent and have
inalienable rights. Among these are enjoying and defending life and liberty, acquiring, possessing, and
protecting property, and pursuing and obtaining safety, happiness, and privacy. "); PA. CoNsT. art. I, § I
(all people "have certain inherent and indefeasible rights, among which are those of enjoying and
defending life and liberty, of acquiring, possessing and protecting property and reputation, and of
pursuing their own happiness"); WASH. CONST. art. I, § 7 ("No person shall be disturbed in his private
affairs, or his home invaded, without authority of law."). For a discussion of Washington's privacy
protection in the context of protecting the individual's right to refuse medical treatment, see Comment,
Artificial Nutrition and the Terminally Ill: How should Washington Decide?, 61 WASH. L. REv. 418
(1986).
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choose, neither model adequately protects the patient's dignitary interest.22
In attempting to fashion workable models, the courts have focused far
too much attention on the narrow question of the physician's duty to warn.
Instead, courts should examine and emphasize the larger question of the
physician's obligation to communicate sufficient information to permit the
patient to make an informed choice. Courts have lost sight of the impor-
tance of allowing individual patients to make their own decisons, a concept
that lies at the core of every patient's right to self-determination.2 3 Rather
than emphasizing the individual's right to choose, courts have adopted a
highly deferential attitude towards the medical profession that permeates
the entire field of informed consent.
A. Protecting the Patient's Right to Choose: Current Models
In general, courts apply the doctrine of informed consent in cases that
concern bodily invasive procedures such as surgery,24 exploratory diag-
nostic techniques,2 and radiation treatment.26 Courts apply either the
medical-community or the objective-patient model to determine whether a
patient gave an informed consent to one of these invasive procedures. Each
model includes standards for determining the three essential doctrinal
elements of informed consent: whether the physician had a duty to disclose;
the scope of that duty (what procedure-specific information must be dis-
closed); and, if the duty was breached, whether the breach proximately
22. At least one court has observed that the objective-patient standard severely limits the protection
granted an injured patient. Scott v. Bradford, 606 P.2d 554, 559 (Okla. 1979). The Scott court stated
that "[t]o the extent the plaintiff, given an adequate disclosure, would have declined the proposed
treatment, and a reasonable person in similar circumstances would have consented, a patient's right of
self-determination is irrevocably lost." Id. (emphasis in original); see also McPherson v. Ellis, 305
N.C. 266, 273, 287 S.E.2d 892, 897-99 (1982) (the subjective standard allows consideration to be
given to the particular quirks and idiosyncrasies of the individual); Katz, Informed Consent-A Fairy
Tale?-Law's Vision, 39 U. Prrr. L. REv. 137, 140, 163 (1977); Seidelson, Medical Malpractice:
Informed Consent Cases in "Full Disclosure" Jurisdictions, 14 DUQ. L. REv. 309, 319-20 (1976).
The objective standard of disclosure does not ensure the right of each individual to decide what will
be done with his or her own body. "The belief that there is one 'reasonable' or 'prudent' response to
every situation inviting medical intervention is nonsense, from the point of view of both the physician
and the patient." J. KArz, supra note 5, at 76.
23. See supra notes 16, 21 and accompanying text.
24. See, e.g., Canterbury v. Spence, 464 F.2d 772 (D.C. Cir.), cert. denied, 409 U.S. 1064 (1972);
Harnish v. Children's Hosp. Medical Center, 387 Mass. 152,439 N.E.2d 240 (1982); Scott v. Bradford,
606 P.2d 554 (Okla. 1979).
25. See, e.g., McPherson v. Ellis, 305 N.C. 266, 287 S.E.2d 892 (1982); Cooper v. Roberts, 220
Pa. Super. 260, 286 A.2d 647 (1971); Scaria v. St. Paul Fire & Marine Ins., 68 Wis. 2d 1, 227 N.W.2d
647 (1975).
26. See, e.g., Natanson v. Kline, 186 Kan. 393, 350 P.2d 1093 (1960); Wilkinson v. Vesey, 295
A.2d 676 (R.I. 1972).
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caused the patient's injury (that is, whether the patient would not have
consented to the procedure had adequate disclosure been made).
The medical-community model is the most widely accepted model for
evaluating claims alleging the lack of informed consent. Under this
model, courts use the practice of the local community of physicians as the
standard for determining the existence and scope of the individual physi-
cian's duty to disclose. 27 The patient has no right to know about
therapeutic risks unless the medical community collectively has deter-
mined to disclose those risks. 28 Physicians breach their duty to inform by
failing to disclose the alternatives and risks that practitioners in the medi-
cal community would have disclosed. 29 However, even when a breach
occurs, patients must demonstrate that the failure to inform proximately
caused their injuries. To do so the patient must prove that the hypothetical
reasonable patient would not have agreed to take the drug had the physi-
cian made the required disclosure.30 Therefore, the proximate cause deter-
mination does not depend on what choice the particular patient would
have made. 31
Although the proximate cause component of the medical-community
model takes a more patient-oriented approach than the physician-oriented
duty and scope components, courts that ignore the concerns and desires of
the particular patient in favor of the hypothetical patient cannot effect the
patient's right of self-determination and bodily integrity. In most cases,
therapeutic preferences of hypothetical patients do not represent the unique
concerns of particular, individual patients. 32
Because of the overly deferential aspects of the medical-community
model, a significant number of jurisdictions have adopted the reasonable-
patient perspective for evaluating the three components of the informed
27. See supra note 8.
28. See Kaiser v. Suburban Transp. Sys., 65 Wn. 2d 461,464,398 P.2d 14. 16 (1965) (to determine
what warnings are to be given with a prescription drug, a court should look to what the medical
community usually discloses); Natanson v. Kline, 186 Kan. 393, 350 P.2d 1093, 1106 (1960) ("The
duty of the physician to disclose . . . is limited to those disclosures which a reasonable medical
practitioner would make under the same or similar circumstances.").
29. See, e.g., Watkins v. United States, 482 F. Supp. 1006, 1012-13 (M.D. Tenn. 1980); Finley v.
United States, 314 F. Supp. 905, 911-12 (N.D. Ohio 1970); Koury v. Folio, 772 N.C. 366, 158 S.E. 2d
548, 554 (1968).
30. See Canterbury v. Spence, 464 F.2d 772, 791 (D.C. Cir.) ("If adequate disclosure could
reasonably be expected to have caused [a prudent person in the patient's position] to decline the
treatment . . .causation is shown, but otherwise not."), cert. denied, 409 U.S. 1064 (1972). As to
proximate cause, both the medical-community and objective-patient models apply the reasonable-
patient standard. See infra notes 32, 42, and accompanying text.
31. See supra note 22.
32. The reasonable-patient approach has been criticized as "backtracking on . ..[the] theory of
self-determination." Scott v. Bradford, 606 P.2d 554,559 (Okla. 1979). The basic rights to know and to
decide are the reasons for adopting a full-disclosure rule. Id.
372
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consent doctrine. 33 The most notable adoption of an objective-patient
model came in Canterbury v. Spence,34 where the court recognized the
importance of protecting the patient's dignitary interest and attempted to
develop its model accordingly. The objective-patient model developed out
of courts' recognition that physicians, given their medical knowledge and
perspective, tend to view the therapeutic choice with certainty.35 Typically,
the physician can see only one reasonable course of therapy in a given
situation, and therefore sees no need to discuss with the patient the possible
alternatives and the potential risks.36
Patient-oriented courts assume that if left with the freedom to choose,
physicians would usually decide not to share the information necessary for
patients to make their own therapeutic choices. This presumption of non-
disclosure is another reason why patient-oriented courts reject the medical-
community model in favor of the objective-patient model to informed
33. See supra note 9, infra notes 37-38, and accompanying text.
34. 464 F.2d 772, 780 (D.C. Cir), cert. denied, 409 U.S. 1064 (1972). In Canterbury, a patient
suffering from back pain underwent a laminectomy without being informed of a risk of paralysis
incidental to the procedure. Id. at 776-77. The day after the operation, the patient fell after being left
unattended, and the lower half of his body became paralyzed. Id. at 777. Plaintiff's permanent injury
included the inability to walk without crutches, paralysis of the bowels, and urinary incontinence. Id. at
778. The court held that fundamental to American jurisprudence is the premise that "[e]very human
being of sound mind has a right to determine what shall be done with his own body." Id. at 780 (quoting
Schloendorff v. Society of N.Y. Hosp., 211 N.Y. 125, 105 N.E. 92, 93 (1914)). The court went on to
define true consent as an informed exercise of choice that requires the patient to have knowledge of the
risks of and alternatives to the proposed treatment. Canterbury, 464 F.2d at 780. Since physicians.
possess such knowledge, the duty fails upon them to communicate with the patient. The final decision
rests with the patient as it is the patient's prerogative, not the physician's, to determine the patient's own
best interests. Id. at 781.
The scope of the physician's duty to disclose was governed by an objective-patient standard in
Canterbury. Id. at 787. This standard requires the physician to disclose all information potentially
affecting the patient's decision. Id. at 787. With respect to scope of disclosure, the court did not want to
place the burden on the physician to know what each particular patient would consider relevant;
therefore, the physician was only required to disclose what the average, reasonable patient would
consider material under the circumstances. Id. As to proximate cause, Canterbury also adopted the
objective-patient standard. Id. at 790-91. Causation would be found only where a reasonable patient
would have refused treatment had adequate disclosure been made. Id. at 791. The court rationalized its
adoption of an objective standard by reasoning that the adoption of a purely subjective patient standard
would place the physician at the mercy of the patient's self-serving hindsight testimony. Id. at 790.
35. The Canterbury court observed that "[t]o the physician, whose training enables a self-
satisfying evaluation, the answer may seem clear, but it is the prerogative of the patient, not the
physician, to determine for himself the direction in which his interests seem to lie." 464 F.2d at 781.
36. Canterbury, 464 F.2d at 783-84. Judge Robinson observed that:
[Tihe reality of any discernible custom reflecting a professional concensus on communication
of option and risk information to patients is open to serious doubt. We sense the danger that what in
fact is no custom at all may be taken as an affirmative custom to maintain silence, and that
physician-witnesses to the so-called custom may state merely their personal opinions as to what




consent. 37 The patient's rights of bodily integrity and self-determination
require that the patient receive the information necessary to make an
informed therapeutic decision. In order to guarantee that the patient re-
ceives the necessary information, patient-oriented courts have decided that
the judiciary has the responsibility for determining when the duty to inform
attaches, rather than allowing the community of physicians to make that
determination. 38
Optimally, the duty to inform ought to require the physician to disclose
therapeutic alternatives and risks and all other information that would be
material to the particular patient's opportunity to make an informed
choice. 39 This optimal standard is subjective, rather than objective, because
it requires the disclosure of information significant to the particular pa-
tient's decision. 40 Nevertheless, the "reasonable patient"' courts uniformly
back away from the subjective individual-patient standard in order to
protect the medical profession at the expense of individual patient's rights
of self-determination and bodily integrity. 4'
Objective-patient model courts, like their medical-community model
counterparts, reject a subjective-patient standard for determining proxi-
mate cause. Courts almost universally apply the objective-patient, proxi-
mate cause test in informed consent cases by requiring the trier of fact to
answer the following question: Would a "reasonable" patient have con-
sented to the medical procedure if the physician had made an adequate
disclosure of the alternatives to and the risks associated with the proposed
treatment? The objective-patient standard fails to protect the right of
37. Id. at 783-84.
38. The duty to disclose "is a duty imposed by law which governs [the physician's] conduct in the
same manner as others in a similar fiduciary relationship. To hold otherwise would permit the medical
profession to determine its own responsibilities to the patients in a matter of considerable public
interest." Cooper v. Roberts, 220 Pa. Super. 260, 286 A.2d 647, 650 (1971) (quoting Berkey v.
Anderson, I Cal. App. 3d 790, 82 Cal. Rptr. 67, 78 (1970)); see also Canterbury v. Spence, 464 F.2d
772, 784 (D.C. Cir.), cert. denied, 409 U.S. 1064 (1972) ("Respect for the patient's right of self-
determination on particular therapy, demands a standard set by law for physicians rather than one which
physicians may or may not impose upon themselves.") (footnotes omitted).
39. See, e.g., Canterbury, 464 F.2d at 787 ("Optimally for the patient, disclosure of a risk would
be mandatory whenever the patient would deem it significant to his decision."); Cooper v. Roberts, 220
Pa. Super. 260, 286 A.2d 647, 650 (1971) (primary interest of informed consent is that of "having the
patient informed of all the material facts from which he can make an intelligent choice as to his course of
treatment, regardless of whether he in fact chooses rationally").
40. Canterbury, 464 F.2d at 787; Cooper v. Roberts, 220 Pa. Super. 260, 286 A.2d 647, 650
(1971).
41. Canterbury, 464 F.2d at 787 (determining that a subjective standard of disclosure would
unfairly require the physician to "second-guess" the patient, "whose ideas on materiality could hardly
be known to the physician"); Cooper v. Roberts, 220 Pa. Super 260, 286 A.2d 647, 650 (1970)
(subjective standard would require physicians to be mindreaders). But see infra notes 65-70, 76 and
accompanying text.
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"subjective" patients to make their own therapeutic choices. 42 Neverthe-
less, of the currently available informed consent models, the objective-
patient model is preferable. It effects a more thoughtful and thorough
doctrine of informed consent that expressly recognizes the need to protect
the patient's rights of bodily integrity and self-determination. 43 Courts that
have adopted the objective-patient model have recognized, at least im-
plicitly, that patient idiosyncrasies affect a patient's ability to make an
informed choice. 44
However, in backing away from a subjective-patient standard for deter-
mining proximate cause,45 courts have compromised the rights of individ-
ual patients. Both of the currently available informed consent models deny
patients the opportunity to hold their own peculiar values and to make their
own informed choices. This almost universal failure by the courts to protect
the patient's dignity interest 46 arises out of the automatic deference courts
assign to judgments made by the medical profession. Unless courts recog-
nize and evaluate the underlying causes of this automatic deferential
response to medical authorities, which is incompatible with the concept of
42. See supra notes 22, 32 and accompanying text; infra note 70 and accompanying text.
43. McClellan, Informed Consent to Medical Therapy and Experimentation, 3 J. LEGAL MED. 81,
103 (1982). Professor McClellan views the Canterbury approach, see supra note 35, as the best
accommodation between concerns for human integrity and respect for professional expertise. Id. Much
of the criticism of Canterbury misses the point because it focuses on a single value or goal. Id. The
Canterbury approach views the problem systematically and comprehensively in light of fundamental
values and practicalities. Id.
44. See supra notes 38-40 and accompanying text.
45. In Canterbury, the court explained its refusal to adopt a subjective-patient standard by
observing that:
when causality is explored . . . with a professedly uninformed patient, the question whether he
actually would have turned the treatment down if he had known the risks is purely hypo-
thetical . . . And the answer . . . hardly represents more than a guess, perhaps tinged by the
circumstance that the uncommunicated hazard has in fact materialized.
Canterbury, 464 F.2d at 790 (footnotes omitted). For a discussion of the physician's duty to communi-
cate in a subjective-patient model, see infra notes 266-68 and accompanying text. But see infra note 90.
46. Violations of a person's dignitary interest necessarily involve an interference with the right to
self-determination. J. KATz, supra note 5, at 79. Dignitary interest violations are not limited to those
involving physical harm; lack of informed consent is itself a violation. "The additional presence of
physical harm only adds injury to insult." Id. In Canterbury, the court accepted the traditional
requirement that the undisclosed risk must materialize for liability to attach. 464 E2d at 790. By failing
to attach legal consequence to the unpardonable omission, however, the court severely limits protection
of the dignitary interest. Courts do not have to infringe patients' dignitary interests in order to preserve
the traditional requirement that risks must materialize before a claim is actionable. Courts could strike a
fairer balance between protection of patients' dignitary interests and the preservation of the traditional
tort scheme by maintaining physical injury as an element of plaintiff's claim in order to protect
physicians from harassment suits, see infra notes 90, 274-80 and accompanying text, but at the same
time recognize the needs and interests of the particular, subjective patient in shaping the duty, scope,
and proximate cause standards. See infra notes 264-81 and accompanying text.
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patient self-determination, there is little prospect that the patient's digni-
tary interest can be effectively protected.
B. Deference to the Medical Community
Judicial deference to the medical profession is endemic in the entire field
of informed consent. 47 Considering that courts have little difficulty impos-
ing legal standards upon other professions and specialist groups, 48 it is
remarkable that they are so willing to have the medical profession deter-
mine for itself the existence and scope of the duty to disclose information to
patients. 49 To examine the judicial response to informed consent in pre-
scription drug cases, one must understand why courts defer to the medical
profession generally.
There are four general reasons why courts defer to the medical profession:
(1) lack of understanding of the knowledge and practice of medicine, which
creates a judicial fear of destroying the physician-patient relationship; (2) a
belief shared with society at large that physicians know what is best for their
patients; (3) a belief that physicians already tell patients all that patients need
to know; and (4) reluctance to interfere with the application of an esoteric
body of knowledge. While these reasons interact at different times and
manifest themselves in various forms in both of the existing informed
consent models, each reason for judicial deference must be examined
individually in order to understand its full impact on the judiciary.
It appears that judges believe that they lack familiarity with and under-
standing of the practice of medicine and its concomitant body of knowl-
edge. 50 Consequently, courts are reluctant to impose legal standards that
would pose unique and difficult questions regarding medical practice. 5'
Instead, judges have based the legal standard for physicians' behavior on
47. J. KATZ, supra note 5, at 49, 82-84; S. SAGov, THE ACTIVE PATIENT'S GUIDE TO BETTER
MEDICAL CARE 125 (1976); Comment, Informed Consent: From Disclosure to Patient Participation in
Medical Decisionmaking, 76 Nw. U.L. REV. 172, 176 (1981). See generally Shapiro, Limiting Physi-
cian Freedom to Prescribe a Drug For Any Purpose: The Need for F.D.A. Regulation, 73 Nw. U.L.
REV. 801 (1978).
48. See McClellan, supra note 43, at 94-95.
49. See supra notes 8, 28, and accompanying text; infra notes 61-63 and accompanying text: see
also T. PRESTON, THE CLAY PEDESTAL 190-91 (1981).
50. See, e.g., Frankfurter, A Lawyer's Dicta on Doctors, Tile George W Gay Lecture upon
Medical Ethics at Harvard Medical School, HARV. MED. ALUMNI BULL. 12, 17 (July 1958) ("I am not
competent to have any views on the very difficult problem of the relations between the medical
profession and society.").
51. J. KATz, supra note 5, at 82 ("What are the risks and benefits of the proposed treatment and of
no treatment? Which ones did physicians have to be aware of? How much are they required to know
about them? Which ones are they required to disclose?").
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actual medical practices, rather than on a judicially derived theory.52 It is
generally recognized that the majority of patients tend to exhibit a deferen-
tial attitude toward their physicians. 53
Judges may also believe, like much of the rest of society, that doctors
know better than patients what is good for them.54 Apparently, courts fear
that patients are incapable of participating in medical decisionmaking. 55
Courts also fear that imposing changes on the traditional physician-patient
relationship will interfere with patients' unquestioned faith in their doctors,
52. Id. at 69; see also Katz, supra note 22, at 140; McClellan, supra note 43, at 95.
53. T. PRESTON, supra note 49, at 66-67 (physician-patient relationship is similar to that of parent-
child, where the child-like patient does what the physician says with few avenues for appeal). But see 2
PRESIDENT'S COMMISSION, supra note 5, at 140 table 4-7 (only 38% of the public believes the physician
has the right to withhold information if it might make the patient unwilling to undergo the treatment);
id. at 239 table 8-1 (43% of the public wants the final decision to be up to them; 38% want the final
decision to rest with the physician); Roter, PhysicianiPatient Communication: Transmission of Infor-
mation and Patient Effects, 32 MD. ST. MEo. J. 260,260 (1983). For discussion of "paternalism", seeJ.
KATz, supra note 5, at 27 (doctors feel patients lack the capacity to make final decisions); Katz, supra
note 22, at 140; Comment, Warnings and the Pharmaceutical Companies: Legal Status of the Package
Insert, 16 Hous. L. REv. 140, 163 (1978) (physician views the patient as a sick child).
54. J. KArz, supra note 5, at 59; R. MENDELSOHN, supra note 5, at 150-56; Trichter & Lewis,
Informed Consent: The Three Tests and a Modest Proposal for the Reality of the Patient as an
Individual, 21 S. TEx. L.J. 155, 164 (1981).
55. See Katz, supra note 22, at 148 (doctors believe patients are not emotionally equipped to make
final decisions and judges will not intrude); see also J. KATz, supra note 5, at 59 (concern for protecting
patient's best interests prevailed over protecting patient's rights of self-determination and liberty); 2
PRESIDENr's COMMISSION, supra note 5, at 137 table 4-4 (only 17% of physicians think all theirpatients
want a candid disclosure). In the court's view, doctors know what the patients' best interests are better
than the patients do. But cf. id. at 136 table 4-3 (94% of the public wants to know everything about their
medical condition even if it is unfavorable); Andrews, Informed Consent Statutes and the Decisionmak-
ing Process, 5. J. LEGAL MED. 163, 171, 178 (1984) (doctors misjudge patients' ability to understand);
Roter, supra note 53, at 260 (doctors underestimate patients' knowledge).
In the prescription drug context, the courts have created a legal role for the physician vis-a-vis the
patient and the drug manufacturer. See Lukaszewicz v. Ortho Pharmacuetical Corp., 510 F. Supp. 961,
963 (E.D. Wis. 1981). American courts universally hold that in the case of prescription drugs, the
manufacturer's duty to warn is satisfied by proper warnings to a physician because the patient cannot
obtain the drug except through the physician. Id. This implies that the physician is sufficiently
knowledgeable about pharmacology to play his part as the learned intermediary between patient and
manufacturer. See Dixon, Drug Product Liability: Information for Safety, TRIAL, November 1980, at
62, 65-66; Pruzan, Prescription Drug Liability in the Context of Washington Law, 9 GONZ. L. RaV.
707, 718 (1974); Rheingold, Products Liability-The Ethical Drug Manufacturer's Liability, 18
RUTrERS L. REv. 947, 987 (1964); Note, Torts: Unavoidably Unsafe Drugs-An Oklahoma Modifica-
tion, 20 OKLA. L. REv. 252, 256 (1976).
while it has been argued that physicians have a duty to educate themselves about the pharmacology
of drugs, and the courts base the physician's learned intermediary role on the assumption that
physicians in fact have pharmacological expertise and knowledge about particular drugs, there is
evidence that physicians are not sufficiently knowledgeable about either pharmacology in general or
particular drugs. See, e.g., R. MENDELSOHN, supra note 5, at 65 (doctors prescribe tranquilizers freely,
but as one study of Librium demonstrated, half of the doctors asked to identify the active ingredient
could not do so).
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which will undermine the prospects for a cure.56 Thus, judicial deference
indicates that judges fear that a legal standard will unduly affect, and
perhaps destroy, the practice of medicine as it currently exists. 57
Judges tend to believe that their legal rulings on informed consent simply
condone the usual behavior of physicians, 58 in effect creating a presump-
tion of due care. Because of this belief, courts assume that physicians, as
part of providing due care, ordinarily disclose facts sufficient for informed
consent. Therefore, courts set the standard of disclosure by reference to the
"reasonable medical practitioner."' 59 The judicial faith in physicians'
willingness and desire to disclose and share aspects of decisionmaking with
patients results from courts' failure to understand the tradition of physician
autonomy and noncommunication. 60
Finally, courts have now developed a tradition of judicial deference, even
powerlessness, vis-a-vis the medical profession. This traditional attitude is
founded, in part, on an early belief that the responsibility for protecting
patients from medical misadventure lay within the province of legislatures
and enlightened public opinion. 61 Modern courts have continued this
deferential tradition by their reluctance to impose legal demands upon
medical judgment when such demands intrude into areas believed to be
"solely the province of medicine." 62 Judicial reluctance to "interfere" in
the practice of medicine may originate in a recognition that "[a]ll profes-
sions possess esoteric knowledge that, in its totality, is difficult to learn,
56. J. KATZ, supra note 5, at 71. A significant number of physicians believe that by "'[filling] a
patient with uncertainties, [torturing] them with potentialities, however remote,"' a physician "endan-
gers patients' mental and physical life and 'destroys good patient care."' Id. at 27 (footnotes omitted);
see also R. BURT, TAKING CARE OF STRANGERS 102-05 (1979).
57. See J. KATZ, supra note 5, at xv; 2 PRESIDENT'S COMMISSION, supra note 5, at 200 table 6-8
(physicians feel they have duty to persuade); Meisel & Roth, What We Do and Do Not Know About
Informed Consent, 246 J. A.M.A 2473, 2476 (1981) (no conclusive studies have been made on whether
giving patients full disclosure will discourage them from consenting to the treatment); see also ZeBarth
v. Swedish Hosp. Medical Center, 81 Wn. 2d 12, 499 P.2d 1 (1972), overruled, Miller v. Kennedy, 85
Wn. 2d 151, 530 P.2d 334 (1975) (per curiam).
58. See, e.g., Finley v. United States, 314 F. Supp. 905, 911 (N.D. Ohio 1970). The court found that
a presumption of negligence does not arise from the fact that a bad or unexpected result occurs. In fact,
the court held that there is a presumption of due care that the injured party must overcome. Id.
59. See, e.g., Natanson v. Kline, 186 Kan. 393,350 P.2d 1093, 1106 (1960). The Kline court stated:
So long as the disclosure is sufficient to assure an informed consent, the physician's choice of
plausible courses should not be called into question if it appears, all circumstances considered,
that the physician was motivated only by the patient's best therapeutic interests and he proceeded
as competent medical men would have done in a similar situation.
Id. See also J. KATZ, supra note 5, at 2-3.
60. J. KATZ, supra note 5, at 3. It is not surprising that defendant physicians in prescription drug
cases argue that they do not have a duty to communicate with the patient. See, e.g., Sharpe v. Pugh, 277
N.C. 598, 155 S.E.2d 108 (1967); Boyer v. Smith, No. 80-12190-6, slip op. at 5 (C.P. Bucks County,
Pa., Jan. 28, 1985), aff'd, 497 A.2d 646 (Pa. Super. 1985).
61. J. KATZ, supra note 5, at 36; Frankfurter, supra note 50, at 177.
62. J. KATZ, supra note 5, at 74.
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understand, and master" and that "the complexity of professional knowl-
edge commands the laity to listen carefully to experts. ", 63 Courts then seem
to conclude that only experts within the profession, the persons who have
learned, understood, and mastered the esoteric knowledge, can determine
appropriate standards for the behavior of the profession.
Of the available models of informed consent, the medical-community
model represents the extreme of deference to the medical profession. In
using the practice of the community of physicians to determine both the
existence and the scope of the duty to communicate with patients, courts
ignore the vital role of the patient. Instead, courts make a variety of
assumptions, all tending toward the conclusion that patients are not capable
of participating in therapy decisionmaking and that the physician, the only
party that understands the choices, should unilaterally determine the cor-
rect therapy.64
While those assumptions have some logical appeal, it is not necessarily
accurate to infer, as this approach does, that professional knowledge
"cannot be communicated to, or understood by, patients." 65 Nor should
one conclude that because professionals have mastered this esoteric knowl-
edge, they should unilaterally decide how to proceed without consulting
patients, especially when alternatives exist and the success of treatment is
uncertain. 66
For whatever reason, courts, even those adopting the objective-patient
model, seem to have concluded, with almost dogmatic determination, that
effective communication between physicians and patients is not possible. 67
As a result, regardless of which model is employed, courts do not impose a
duty of full communication on physicians, 68 which is to the detriment of
63. Id. at 92.
64. See Watkins v. United States, 482 F. Supp. 1006, 1012 (M.D. Tenn. 1980) (physician has duty
to use own bestjudgment in treating the patient); Finley v. United States, 314 F Supp. 905, 914 (N.D.
Ohio 1970) (medical questions are a technical and specialized subject matter and require medical
experts to set the standards). Doctors believe that patients are better protected if they trust their doctors'
authority and have confidence in the medical community's altruistic dedication. L KATZ, supra note 5,
at 91.
65. L KAxz, supra note 5, at 92. See infra notes 66-68 and accompanying text.
66. J. KA'z, supra note 5, at 92. In order to safeguard the autonomy of both parties, medical
decisionmaking must become a joint undertaking. Professor Katz believes that the complexity of
professional knowledge requires the laity to listen carefully to experts. He does not suggest, however,
that physicians cannot communicate with individual patients or make them understand. According to
Katz, physicians cannot dispute patients' ability to understand because the medical community has had
too little experience communicating their esoteric knowledge. Id.
67. See, e.g., Canterbury v. Spence, 464 E2d 772,787 (D.C. Cir.) (physicians cannot know with
complete certainty what particular patients would consider important to their decisions), cert. denied,
409 U.S. 1964 (1972).
68. Id. at 787 (physicians, using their "medical training and experience . ..can sense how the
average, reasonable patient expectably would react") (footnote omitted).
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the particular patient, who has needs, priorities, and preferences different
from those of the "reasonable" patient. 69 Of course, in reality, the
physician can ask patients about their needs and explain carefully every
alternative to the proposed therapy, including no therapy, as well as the
risks associated with each alternative. In this manner the physician can
come to understand with reasonable certainty the facts material to the
particular patient's decision to choose one therapy from various alter-
natives, including the one recommended by the physician. 70
Thus, the objective-patient model of informed consent manifests a high
level of deference, although much less than that of the medical-community
model. The objective-patient model moves away from deference by recog-
nizing patients' rights of bodily integrity and self-determination. 71 But
while an objective-patient standard initially seems to protect patient rights,
courts using this model ultimately defer to the medical profession. In
Canterbury v. Spence, the court gave two reasons for applying an objective
standard to the scope of the duty to disclose in the general informed consent
context: physicians cannot know individual patients well enough to deter-
mine what information is material to their personal choices;72 and the scope
of the duty to inform ought, in fairness, to be controlled by an objective
rather than a subjective standard. 73 In effect, these courts balance the
individual patient's rights of bodily integrity and self-determination against
a judicial interest in treating physicians fairly.7 4
69. Scott v. Bradford, 606 P.2d 554, 559 (Okla. 1979) ("To the extent the plaintiff, given an
adequate disclosure, would have declined the proposed treatment, and a reasonable person in similar
circumstances would have consented, a patient's right of self-determination is irrevocably lost.")
(emphasis in original): J. KATZ, supra note 5, at 76 ("The belief that there is one 'reasonable' or
'prudent' response to every situation inviting medical intervention is nonsense, from the point of view
of both the physician and the patient."); see also Comment, Informed Consent in Medical Malpractice,
55 CALIF. L. REv. 1396 (1967) (suggesting that there must be standards imposed by courts because each
patient is mentally and emotionally unique).
70. J. KATZ, supra note 5, at 78.
71. See supra note 34 and accompanying text.
72. 464 F.2d 772, 787 (D.C. Cir.), cert. denied, 409 U.S. 1064 (1972). The scope of disclosure
must be objective because physicians cannot possibly know what the patient considers important, and
therefore, physicians need leeway in their decisionmaking. Id.; see also Cooper v. Roberts, 220 Pa.
Super. 260, 286 A.2d 647, 650 (1971).
73. See Canterbury, 464 F.2d at 787; Cooper v. Roberts, 220 Pa. Super. 260, 286 A.2d 647, 650
(1971). Courts adopting the objective model believe that holding physicians to a subjective standard of
disclosure would be placing upon them an unreasonable burden; it would require them to be mind-
readers. Cooper, 286 A.2d at 650-51. According to these courts, the subjective-patient standard
"places the physician in jeopardy of the patient's hindsight and bitterness." Canterbury, 464 F.2d at
790-91. The patient's testimony would be tinged with bitterness given the fact that the uncommunicated
hazard has materialized. Id. at 790; see also supra note 45, infra notes 272-74, and accompanying text.
But see infra note 90.
74. The objective-patient standard gives "due regard [to] the patient's informational needs and
[provides] suitable leeway for the physician's situation." Canterbury, 464 F.2d at 787.
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There are two major problems with this rationale. First, the courts erode
a traditional common law right by balancing it against physician interests,
which have no basis in the common law or in any other clearly delineated
right. 75 Secondly, courts assume that physicians cannot know what their
patients think, and that physicians' conduct can be measured fairly only by
an objective reasonableness standard. Both assumptions are question-
able. 76
The assumption that physicians cannot know what information would be
material to a particular patient's therapeutic choices is unjustified. Often,
physicians do not know because they choose not to know.77 In Canterbury,
the leading objective-model case, the court assumed that physicians cannot
know "with complete exactitude" what is significant to particular pa-
tients. 78 Yet the Canterbury court also recognized that because of their
medical knowledge, physicians tend to see only one viable therapeutic
choice in a particular situation. 79 What the court did not consider, however,
is that this medical preference strongly inhibits physicians from recogniz-
ing any necessity to communicate information to patients to facilitate a
choice from among various therapeutic alternatives. 80
Courts' insistence on measuring the conduct of the prescribing physician
by a reasonableness standard does not necessarily require that an objective-
75. Physicians do not have a "right" of the same magnitude as the individual patient's right to self-
determination and bodily integrity. The only physicians' right explicitly recognized in this context is the
rarely mentioned contract right to be paid for professional services rendered. See Gray v. Grunnagle,
423 Pa. 144, 223 A.2d 663, 669 (1966); Bromberger, Patient Participation in Medical Decision-
Making: Are the Courts the Answer?, 6 U. NEw S. WALEs L.J 1, 12-13 (1983).
76. It has been argued that physicians can communicate with individual patients without having to
be "mindreaders" or to "second-guess" what their patients consider material. Physicians can and
should be required to learn new skills, such as "how to inquire openly about their patients' individual
informational needs and patients' concerns, doubts, and misconceptions about treatment-its risks,
benefits, and alternatives. "L KATz, supra note 5, at 78. To protect adequately the right of self-
determination, courts should require the physician to ask patients whether they understand what has
been explained to them. Id. at 78. On the basis of medical knowledge and experience, the physician can
"sense how the average, reasonable patient expectably would react." Canterbury, 464 F.2d at 787
(footnote omitted). But by employing basic communication skills, the physician can also understand
the therapeutic needs and desires of particular patients. The prescription drug context magnifies the
importance of these unique concerns. Courts would appreciate the special case of prescription drugs if
they would examine closely the unique factors surrounding the prescription of drugs. See infra notes
96-152 and accompanying text.
77. See supra notes 35-36 and accompanying text.
78.- 464 F.2d at 787.
79. See supra note 36 and accompanying text.
80. See also supra notes 55-57 and accompanying text; infra notes 133-37, 255-57, and accom-
panying text. Both the physician and the patient feel an overriding necessity that some action be taken.
A prescription often results from this assumption that some definable action must be taken. Physicians
and patients need to accept the fact that often the best action is no action at all.
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patient standard be applied to the scope of the physician's duty to dis-
close. 8 1 Apparently courts confuse the objective reasonableness standard,
which a judge could instruct a jury to use in determining whether a
defendant physician breached the duty to inform (did the physician make a
reasonable attempt to communicate with the particular patient?), with
whether it is reasonable (in the sense of fairness) to require a physician to
communicate with the particular patient in order to learn the patient's
subjective needs.
Courts put forth two reasons for asserting that it is unfair to require
physicians to communicate effectively with individual patients. First,
courts believe that it is impossible for one person to know what another
person really thinks or feels. 82 Much responsible medical opinion, how-
ever, disagrees strongly with the courts in this regard, 'maintaining that
physicians can communicate, just as any other person can, but that they
deliberately choose not to communicate. 83 The second reason, although
less clearly articulated, may be more significant: courts feel that imposing
time-consuming legal requirements on the medical profession would un-
fairly interfere with physicians' busy practices. 84
Despite these reasons, it does not seem unfair to require a professional,
who is providing a critical personal service, to take the time necessary to
make that service as effective and satisfying to each individual patient as
possible. 85 By focusing on fairness to the physician, rather than on
therapeutic effectiveness, courts misplace their concern for the relative
rights of the parties. Even if a duty to communicate results in some
unfairness to the physician, the burden is outweighed by the infringement
of an individual's rights of bodily integrity and self-determination that
results when courts fail to establish a legal, patient-oriented duty to
communicate. 86
81. See infra notes 251-52 and accompanying text.
82. See supra notes 72-73.
83. See supra notes 77-78.
84. Physicians sometimes argue that an "active practice" precludes meaningful dialogue with
patients, and courts sometimes seem to accept that argument. See Kaiser v. Suburban Transp. Sys., 65
Wn. 2d 461,470, 398 P.2d 14, 19 (1965) (Hale, J., dissenting); Boyer v. Smith, No. 80-12190-6, slip op.
at 3 (C.P. Bucks County, Pa., Jan. 28, 1985), aff'd, 497 A.2d 646 (Pa. Super. 1985).
85. This requirement does not seem unfair for three reasons. First, the requirement to communicate
is not onerous. Physicians need not try to second-guess their patients. Instead, they can, and must.
improve their communication skills and inquire into their patients' particular concerns. J. KATZ, supra
note 5, at 78. Second, patients who are not adequately informed tend to do poorly afterwards when
compared to patients who received adequate information. See infra notes 120-21, 254. Finally,
increased communication leads to increased patient satisfaction which, in turn, leads to less litigation.
See infra notes 253, 265.
86. See supra note 75 and accompanying text.
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Courts universally apply the objective-patient standard to determine
proximate cause. 87 In considering whether the patient would have con-
sented to the proposed therapy had the physician given the patient adequate
information, courts generally fear that the "hindsight" testimony of an
injured and perhaps embittered plaintiff would be unfair to the physician. 88
In addition, the Canterbury court believed that hindsight testimony would
force the jury to determine a critical issue on the basis of a speculative
answer to a hypothetical question. 89 Despite this suspicion of hindsight
testimony, some jurisdictions admit plaintiff's testimony on this issue,
even though they determine proximate cause by whether a reasofnable
patient would have consented to the therapy had the physician provided
adequate information about it.90
87. See supra notes 32, 40-42 and accompanying text.
88. See, e.g., Canterbury, 464 F.2d at 790-91; see also supra notes 45, 73 and accompanying text;
infra notes 90, 272, and accompanying text.
89. Canterbury, 464 F.2d at 791. See infra notes 90, 272 and accompanying text.
90. Whether courts adopt a subjective or objective standard, plaintiffs' testimony regarding
causation is suspect from an evidentiary point of view. See discussion of proximate cause, infra notes
269-82 and accompanying text.
Some commentators, as well as the majority of jurisdictions, rely on evidentiary problems to argue
for the objective standard, asserting that the subjective standard would encourage self-serving hindsight
testimony. See, e.g., Liability of Health-Care Providers-Informed Consent-Physician's Duty to
Disclose, 7 AM. J. LAW & MED. 38, 40 (1981). When the causation issue is explored at the trial with a
professedly uninformed patient, whether the patient would actually have turned down the treatment if
the risks were known is purely hypothetical, and the answer supplied by the patient hardly represents
more than a guess, which places the physician in jeopardy of the patient's hindsight and bitterness.
Canterbury, 464 F.2d at 90-9 1. One commentator argues that the subjective standard puts the fact finder
in the position of deciding whether to credit a speculative answer to a hypothetical question. Seidelson,
supra note 22, at 331; see Niblack v. United States, 438 F. Supp. 383, 389 (D. Colo. 1977) (subjective
testimony is regarded with skepticism); Hamilton v. Hardy, 37 Colo. App. 375, 549 P.2d 1099, 1105
(1976) (subjective testimony would be, at best, self-serving and speculative); LeBlang, Informed
Consent-Duty and Causation:A Survey of CurrentDevelopments, 18 THE FORUM 280,287(1982) (the
objective standard protects the physician from patient bitterness).
Nonetheless, other courts besides Canterbury allow such testimony, and commentators support its
admission. See, e.g., Scott v. Bradford, 606 P.2d 554, 559 (Okla. 1979) (careful practitioners can
always protect themselves by insuring that each patient is adequately informed and testimony by the
patient gives jurors the opportunity to evaluate the evidence and weigh the credibility of all witnesses);
see also Note, Medical Malpractice: A Subjective Approach to Informed Consent in Oklahoma, 15
TULSA L.J. 665 (1980).
Subjective testimony should be allowed in informed consent cases as a part of the totality of evidence,
even though it is self-serving. Holt v. Nelson, I I Wn. App. 230,236,523 P.2d 211, 216 (1974). Thejury
will recognize the self-interest underlying the plaintiff's testimony and the defense will emphasize such
self-interest as a critical factor to be considered by the jury in determining the plaintiff's credibility and
the weight to be given to subjective testimony. Seidelson, supra note 22, at 330-31.
Courts adopting the objective model argue that allowing the patient to testify gives the jury an
opportunity to compare the testimony with their belief in its reasonableness, thereby strengthening the
case for a wholly objective causation standard. Canterbury, 464 F.2d at 791.
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Judicial deference to the medical profession is most striking in the
prescription drug context, where courts almost universally apply the medi-
cal-community model. 9' In deferring to the interests of the medical profes-
sion, courts ignore the essential factors that operate in the prescription drug
context. 92 By ignoring these factors, courts invariably reject the subjective-
patient model. This in turn reinforces physicians' narrow view of what
needs to be disclosed and denies patients information most significant to
them personally. 93 Ultimately, the failure to adopt a subjective standard and
the unwarranted deference to the medical profession results in a failure to
protect the patient's right of bodily integrity and self-determination. These
rights are fundamental in Anglo-American law. If courts examined closely
all of the important considerations permeating prescription drug therapy, it
is difficult to imagine that they would allow the mere possibility of a slight
economic infringment on the practice of medicine to infringe on these
fundamental rights.
II. PRESCRIPTION DRUG THERAPY: THE SPECIAL FACTORS
A variety of factors either are unique to the prescription drug setting or
are more prevalent and play a significantly greater role for informed consent
in prescription drug therapy than for informed consent to bodily invasive
procedures. While some obvious interrelationships exist between many of
these factors, each can be regarded as a distinctive aspect of prescription
drug therapy. Courts should recognize and consider these factors in apply-
ing the informed consent doctrine in prescription drug cases. 94 Too often
courts fail to recognize that these factors are at work or, when recognition
occurs, courts disregard the actual effect these factors have in the situation
at hand.95
The failure to take account of these factors affects the patient's ability to
make an informed therapeutic choice and leads to the continuation of
unwarranted judicial deference to the medical community. Although each
special factor has relevance to both courts' attitudes toward informed
91. See infra notes 153-58 and accompanying text.
92. See infra notes 96-152, 162-230 and accompanying text.
93. J. KATZ, supra note 5, at 76 (arguing that it is nonsensical to believe that there is a single
"reasonable" or "prudent" person response to every medical situation).
94. See infra notes 96-161 and accompanying text.
95. See infra notes 162-233 and accompanying text. Although state legislatures do not appear to
have responded specifically to the prescription drug situation, lawmakers do seem to defer to the
medical profession's complaints to the detriment of patients' rights and needs. See Andrews, supra note
55, at 179. Not only is inadequate attention paid to state informed consent requirements, they are not
enforced. Id.; see 2 PRESIDENT'S COMMISSION, supra note 5, at 176 table 5-13 (an average of 76% of
physicians do not know applicable informed consent standards in their state).
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consent in the prescription drug context and to the patient's decisionmak-
ing process, it is helpful to divide them them into two groups. First, factors
such as the pervasiveness of prescription drug use, the tendency of physi-
cians to overprescribe these drugs, and the narrow limits of physicians'
pharmacological knowledge have been almost universally ignored under
the medical-community model. Second, factors, such as the way in which
personal idiosyncrasies are relevant to the choice of therapy, must be
understood by patients in order to make an informed choice. Patients also
need to know the range of treatment alternatives and to understand the risks
of side effects in order to participate in the constant monitoring required
during prescription drug therapy.
A. Factors That Should Limit Judicial Deference to the Medical
Profession in the Prescription Drug Context
1. The Pervasiveness of Prescription Drugs
Prescription drugs are the most common treatment of all medical
therapy. 96 Ninety million Americans are estimated to take some drug each
week, 97 with the result that the United States has become a "pill-swallow-
ing civilization." 98 Although completely reliable statistical studies are not
available regarding side effects associated with prescription drugs, avail-
able evidence, as well as reliable expert opinion, indicates that as many as
30,000 Americans die each year from an adverse drug reaction. 99 While no
96. 1 PRESIDENT'S COMMISSION FOR THE STUDY OF ETHICAL PROBLEMS IN MEDICINE AND BIO-
MEDICAL AND BEHAVIORAL RESEARCH, MAKING HEALTH CARE DECISIONS 121(1982) [hereinafter cited as
I PRESIDENT'S COMMISSION] ("[D]rugs are the most common treatment in all medical care. Most visits
to the doctor result in a prescription being written .... "); see also R. MENDELSOHN, supra note 5, at
197 (author estimates that one billion prescriptions are written in the United States every year);
Wartman, Do Prescriptions Adversely Affect Doctor-Patient Interactions?, 71 AM. J. PUB. HEALTH
1358, 1358 (1981) (prescriptions often result from the assumption that such therapy is a concrete,
definable action that should be the natural outcome of the medical care visit). Overuse of drugs is
epidemic because patients and clinicians rely on drugs to take care of almost all conceivable problems,
most of which do not respond to pharmacologic solutions. T. PRESTON, supra note 49, at 133. The
overriding necessity of clinical physicians is to do something. It would be very unusual for a patient to
leave after a visit to the doctor without some action having been taken. Id. at 146; see also H. LENNARD,
L. EPSTEIN, A. BERNSTEIN & D. RANSON, MYSTIFICATION AND DRUG MISUSE 18-23, 25-27, 32 (1971)
[hereinafter cited as H. LNNARD] (describing drug use and mystification in doctor-patient relationships
generally); Koch-Weser, Fatal Reactions to Drug Therapy, 291 NEw ENG. J. MED. 302, 303 (1974).
(adverse drug effects commonly due to inappropriate pharmacology).
97. Phillips, Adverse Drug Reactions, TRIAL, May 1984, at 44-45.
98. Review of Cooperation on Drug Policies Among the Food and Drug Administration, National
Institutes of Health, Veteran's Administration and Other Agencies: Hearings on S. Res. 27 Before the
Subcomm. on Reorganization and International Organization of the Sen. Comm. on Government
Operations, 88th Cong., 1st Sess. 2107 (1963) (statement of Herbert Rastner, M.D.) [hereinafter cited
as Hearings].
99. R. MENDELSOHN, CONiFESSIONS OF A MEDICAL HERETIC 26, 39 (1979) (20,000 to 30,000 deaths
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statistics exist as to the exact number of adverse reactions each year, there is
little doubt that the number is in the hundred thousands. 100 Concern about
excessive use, numerous adverse reactions, and a high percentage of
addiction to prescription drugs has led some medical experts to conclude
that more than half of all drug prescriptions should not be written. 101
2. The Tendency to Overprescribe Drugs
Modern technology has made possible a large number of prescription
drugs. 102 A large body of opinion in the medical literature indicates that
rapid technological development has caused the clinical practice of medi-
cine to become overly technical, resulting in the tendency of physicians to
overprescribe drugs. 10 3 Aside from increased deaths and other serious
yearly are attributed to adverse reactions to drugs prescribed by doctors-there is no safe drug). See
also R. MENDELSOHN, supra note 5, at 60-62, 74; J. STEIN, MAKING MEDICAL CHOICES 86 (1978);
Koch-Weser, supra note 97, at 302 (University of Florida study found that 177 (2.9%) of 6063 patients
were admitted because of drug-induced illness and that eleven of these died before discharge).
100. T. PRESTON, supra note 49, at 133 (drug reactions or complications are responsible for 5% of
all hospital admissions in the United States, or as many as 1,500,000 persons per year, which may
represent just a small part of those harmed by drugs); see also R. MENDELSOHN, supra note 99, at 26.
In 1976, doctors wrote twenty-seven million prescriptions for sleeping pills-one billion doses in all.
These prescriptions resulted in about 25,000 "harrowing" trips to hospital emergency rooms, including
5,000 deaths. R. MENDELSOHN, supra note 5, at 60-61. Valium alone produces about 50,000 patients
per year for hospital emergency rooms. Id. See generally H. LENNARD, supra note 96, at 32-35. Not all
adverse side effects result in death or serious injury, but most are potentially dangerous enough to
warrant concern. Taken over a period of time, many drugs have nutritional side effects. Many drugs
cause a loss of appetite. Antacids can lead to phosphate and vitamin D deficiencies. The oral
contraceptive is especially dangerous because it usually is taken for a long period of time and can cause
vitamin B, B6, and C depletions. See Roe, Drugs, Diet and Nutrition, CONTEMP. NUTRmON, June
1978, at 2.
101. T. PRESTON, supra note 49, at 133-34. It has been suggested that a large part of the excessive
use of prescription drugs can be attributed to physicians' psychological need to maintain control of
treatment by appearing to have the certain solution to the medical problem. H. LENNARD, supra note 96,
at 27, 34; see also supra notes 56, 80 and accompanying text; infra note 150 and accompanying text.
102. See S. KLAw, THE GREAT AMERICAN MEDICINE SHOW 23 (1975). The pharmaceutical industry
offers the public more and more over-the-counter drugs for every conceivable human condition and
continues to reinforce the erroneous redefinition of all human problems as medical ones. Id. "An
inordinate number of this year's drugs were developed to cure the damage caused by a miracle drug that
was proudly announced in some previous year. Repeatedly, new drugs are sold to counter the symptoms
produced by others." R. MENDELSOHN, supra note 5, at 58. The pharmaceutical industry and the
medical profession maintain a very close relationship, so that it is in both groups' interest to maintain
large numbers of persons on drugs and to define more and more problems as medical in order to justify
intervening with drugs. Id. at 62-63; see also supra note 96.
103. 1 PRESIDENT'S COMMISSION, supra note 96, at 33; Hearings, supra note 98, at 2107; N.
COUSINS, ANATOMY OF AN ILLNESS AS PERCEIVED BY THE PATIENT 124, 126 (1979); S. KLAW, supra note
102, at 106; R. MENDELSOHN, supra note 5, at 60-61; R. MOSER, DISEASES OF MEDICAL PROGRESS: A
STUDY OF IATROGENIC DISEASE 809-10 (1969); S. SAGov, supra note 47, at 104; L. TUSHNET, THE
MEDICINE MEN: THE MYTH OF QUALITY MEDICAL CARE IN AMERICA TODAY 193-210 (1971).
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adverse reactions resulting directly from the overprescription of drugs, I°4
bacteria have developed immunities to overused antibiotics, which indi-
rectly causes additional deaths and injuries. 105
Physicians often prescribe drugs for patients who have no disease at all
or who have only minor or nonemergency conditions.106 Drugs with
serious side effects are regularly prescribed for patients complaining of
adolescent acne, wrinkled skin, or skin rash. 107 The oral contraceptive is
perhaps the most well-known example of a prescription drug that has major
risks of serious side effects, but is nonetheless regularly prescribed for and
used by healthy patients. 108 Moreover, physicians prescribe drugs too often
104. See supra notes 100-02 and accompanying text; see also R. MEaDmsom, supra note 5, at 15.
105. S. KLtv, supra note 102, at 25.
106. 1 PRESMIDENT'S COMMISSION, supra note 96, at 42 (insomnia); H. LENNARD, supra note 96, at
18-23 (anxiety); R. MENDELSOHN, supra note 5, at 60, 61, 67 (nerves); R. MENDELSOHN, supra note
100, at 27 (prednisone is prescribed for minor skin rashes, yet can damage the reproductive system); T.
PREON, supra note 49, at 21.
107. R. MENDELSOHN, supra note 99, at 27; T. PRETON, supra note 49, at 131. The application of
drugs to the solution of primarily nonmedical problems was demonstrated in a report that concluded
that 5-10% of the 62,000 school children in Omaha were described as being generally hyperactive and
were being given behavior modification drugs. H. LENNARD, supra note 96, at 31. The drugs were
distributed to thousands of children, apparently in disregard of Food and Drug Administration warnings
that the prescribed drugs were addictive and should be used with extreme caution. Id.
108. M. Mnrz, THE PILL 11 (1970). Recent decisions in oral contraceptive cases raise important
questions regarding the application of the informed consent doctrine to the prescription drug context.
Two jurisdictions have held that manufacturers of oral contraceptives can no longer fulfill their duty to
warn merely by providing physicians with information about side effects. Both courts held that
manufacturers of oral contraceptives now must warn users directly of the risks. Lukaszewicz v. Ortho
Pharmaceutical Corp., 510 F. Supp. 961, 965 (E.D. Wis. 1981); MacDonald v. Ortho Pharmaceutical
Corp., 394 Mass. 131, 475 N.E.2d 65, 69, cert. denied, 106 S. Ct. 250 (1985). Both courts recognize
that the general rule with prescription drugs is that the physician acts as a learned intermediary and that
the manufacturer satisfies its duty to warn by providing proper warnings to the physician because the
patient cannot obtain the drug except through the physician. Lukaszewicz, 510 F. Supp. at 963.
However, the courts in both Lukaszewicz and MacDonald held that because of the peculiarities of the
oral contraceptive, the manufacturer must warn the ultimate user of the side effects directly. The
MacDonald court explained its holding as follows:
The oral contraceptive thus stands apart from other prescription drugs in light of the heightened
participation of patients in decisions relating to use of,'the pill'; the substantial risks affiliated with
the product's use; the feasibility of direct warnings by the manufacturer to the user; the limited
participation of the physician (annual prescriptions); and the possibility that oral communications
between physicians and consumers may be insufficient or too scanty standing alone fully to apprise
consumers of the product's dangers at the time the initial selection of a contraceptive method is
made as well as at subsequent points when alternative methods may be considered.
MacDonald, 475 N.E.2d at 70.
To the extent that Lukaszewicz and MacDonald eliminate the role of the physician as the learned
intermediary, they raise several issues regarding patients' rights protected by the doctrine of informed
consent. Both courts appear to assume that the only significant concern involving oral contraceptives is
the risk of side effects inherent in their use. The courts minimize the essential role of the prescribing
physician in informing patients about and discussing. with them alternative forms of contraception,
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for a purpose for which they were never intended. 109 The most prevalent
example of this questionable practice is the use of oral contraceptives to
control breakthrough bleeding and irregular menstrual cycles. 110
Some dispute exists as to whether overprescription is caused by the
medical profession or whether the patient population is overresponding to
the increasing availability of prescription drugs. But whether the pressure
many of which avoid the risks of side effects associated with oral contraceptives. See infra note 135.
Application of the doctrine of informed consent requires a process of communication. The dialogue
between an enlightened physician and an informed patient is as essential to the patient's choice of
alternative contraception as it is to the understanding of the risks peculiar to the use of oral con-
traceptives. See supra note 85, infra notes 240-68, and accompanying text. Courts should be careful
not to substitute products liability law, wherein the physician who is not a seller of the product cannot
have any liability, for the doctrine of informed consent as the basis of the patient's claim. See
RESTATEMENT (SECOND) OF TORTS § 402A (1965). Such a substitution would effectively deny patients
the protection of their right of enlightened self-determination. Nevertheless, since Lukaszewicz and
MacDonald view the physician and drug manufacturer as having concurrent duties based on the
doctrine of informed consent and the law of products liability, respectively, they appear adequate to
protect patients' rights in both contexts. Lukaszeivicz, 510 F. Supp. at 563-64; MacDonald, 475 N.E.2d
at 70.
109. Hearings, supra note 98, at 2140; S. KLAW, supra note 102, at 116; R. MENDELSOHN, supra
note 5, at 58, 65 (3/5 of prescription drugs are not prescribed for their proper use); Mendelsohn, supra
note 99, at 24; J. STEIN, supra note 99, at 86. In one case, the physician negligently prescribed
chloromycetin, a dangerous drug with serious side effects, including aplastic anemia, to a child with
minor throat ailments. The drug was not recommended by the manufacturer to be used for these
conditions. The child developed aplastic anemia and died. Sharpe v. Pugh, 270 N.C. 598, 155 S.E.2d
108 (1967); see also Koury v. Follo, 272 N.C. 366, 158 S.E.2d 548 (1968). In Koury, the physician
injected twice the safe dose of a drug (strep-combiotic) stamped "not for pediatric use" into an infant.
158 S.E.2d at 550. The infant became totally and permanently deaf. Id. The court held that the
physician should have known about this risk and that no immediate emergency existed requiring its use.
Id. at 555. The problem of drugs being prescribed for purposes for which they were not intended
invokes more than just physician liability and the doctrine of informed consent. The manufacturer may
be strictly liable as well under the law of products liability. See supra note 108. In Incollingo v. Ewing,
444 Pa. 263, 282 A.2d 206 (1971), a child was given chloromycetin for a trivial ailment. A second
physician renewed the child's prescription for chloromycetin twice without seeing the child or checking
with the prescribing physician. The child subsequently died of aplastic anemia. The second physician
argued that he felt chloromycetin was safe because of the representations of the Parke, Davis detailmen.
282 A.2d. at 218. This overpromotion defense was also employed by the defendant physician who
prescribed chloromycetin in Stevens v. Parke, Davis & Co., 9 Cal. 3d 51, 107 Cal. Rptr. 45, 507 P.2d
653 (1973). The Food and Drug Adminsitration required Parke, Davis to give notice of chloromycetin's
dangerous and serious side effects, yet Parke, Davis minimized these risks in a letter to its salesmen and
had its salesmen continue concentrated promotions of the drug. 107 Cal. Rptr. at 48, 507 P.2d at 656.
The court found the manufacturer negligent for "watering down" its warning and so overpromoting the
drug that it was prescribed when it was not justified. 107 Cal. Rptr. at 54,507 P.2d at 662; see also supra
note 107.
110. See, e.g., Klink v. G. D. Searle & Co., 26 Wn. App. 951, 614 P.2d 701 (1980) (plaintiff was
prescribed oral contraceptives because of irregular menstrual cycles, she suffered a massive bilateral
stroke, and the court awarded her a million dollar verdict). Oral contraceptives can be linked to more
than 50 side effects ranging from hypertension to diabetes, strokes, heart attacks, and cancer. Since
women have begun taking oral contraceptives, the normal age range of breast cancer victims has gone
from 45-56 to the 30's. R. MENDELSOHN, supra note 5, at 120-29.
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to overprescribe comes from within the medical profession, I"' or is caused
by patient demand1 12 is not the critical issue. Courts, physicians, and
patients must recognize the increased number of side effects that result
from overprescription. Only meaningful physician-patient communication
can prevent the current overuse of drugs. Studies indicate that many
patients would prefer more communication with their physician instead of
the large number of drugs currently prescribed. 113 If the primary cause of
overprescription is patient demand, physicians have an even greater duty to
communicate' 14 and cannot in good conscience use patient demand as the
justification for overprescribing drugs.115
3. The Need for Constant Monitoring
Prescription drug therapy requires constant monitoring, which depends
upon patient awareness of side effects and their symptoms. 116 For the
monitoring process to succeed, patients need to know, for example, which
symptoms are significant and which are not; how to note, measure, and
record symptoms; and when to report these symptoms to their treating
physicians. Obviously this requires greater and more active patient par-
ticipation than that demanded of patients during, or even recovering from,
surgery. The fact that a time lag, and often a significant one, occurs between
the inception of the drug therapy and the side effect1 17 reinforces the
importance of constantly monitoring the therapy and treating the patient as
a coparticipant in the process. 118
Physicians cannot ensure patient compliance with prescription drug
therapy because the patient, not the physician, determines whether to fill
the prescription and whether to follow the directions for use and monitor-
ing. 119 Patient compliance is far from perfect, but it improves when physi-
cian-patient interaction is marked more by shared information than by the
physician's imposition of treatment on a passive patient. 120 Although
111. Hearings, supra note 98, at 2140.
112. Id. at 1303.
113. Wartman, supra note 96, at 1360-61.
114. See Hearings, supra note 98, at 1327; L. TuSHINET, supra note 103, at 199.
115. Hearings, supra note 98, at 2140.
116. M. BELSKY & L. GROSS, How To CHOOSE AND USE Youp DocrOR 95, 107 (1975).
117. R. MENDELSOHN, supra note 5, at 58, 74; see R. MENDELSOHN, supra note 99, at 25, 28.
118. See R. MENDELSOHN, supra note 5, at 58, 74; R. MENDELSOHN, supra note 99, at 25, 28; see
also supra notes 113-15 and accompanying text.
119. S. SAGov, supra note 47, at 102-03; seeM. BELSKY & L. GROSS, supra note 116, at 31, 160,
164; R. MENDELSOHN, supra note 99, at 43-44; Meisel & Roth, supra note 57, at 2474-75; Meyers, The
Effect of Forewarning on the Occurrence of Side-Effects and the Discontinuance of Medication in
Patients on Dothiepin, 122 BRrr. J. PsYcHIATRY 461, 463 (1973).
120. E. MISCHLER, L. AMARASINGHAM, S. OSHERSON, S HAUSER, N. WAXLER & R. LiEM, SOCIAL
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physicians fear otherwise, the available evidence also suggests that patients
do not decline treatment merely as a result of being fully apprised of the
risk of side effects. 121
4. Limited Pharmacological Knowledge and Protection
If the limits of medical knowledge are narrower than is generally
recognized, 122 the limits of pharmacological knowledge are even nar-
rower. 123 Many prescribing physicians rely heavily on pharmaceutical
company salesmen (detailmen) as their primary source of information about
the drugs they prescribe. 124 Physicians also have problems keeping up with
new drugs and the important information relating to their use. 125 Despite the
narrow limits of their knowledge about drugs, physicians often prescribe
them automatically, 126 often without obtaining information about the risks of
side effects, despite readily available sources of drug information, such as
the Physicians' Desk Reference ( "PDR"). 127 Some commentators argue that
physicians provide patients with less information about prescription drugs
with serious risks of side effects than they do about minor surgery. ' 28
Ineffective government regulation of drugs and of the drug industry
compounds the problems created by the limited nature of most physicians'
pharmacological knowledge. The Federal Food and Drug Administraion
(FDA) has the responsibility for protecting public safety by, inter alia,
CONTEXTS OF HEALTH, ILLNESS, AND PATIENT CARE 105-11 (1981) [hereinafter cited as E. MISCHLER].
121. Alfidi, Informed Consent: A Study of Patient Reaction, 216 J. A.M.A 1325, 1329 (1971);
Andrews, supra note 55, at 168 n.25.
122. J. KATz, supra note 5, at 83.
123. Hearings, supra note 98, at 2140; R. MENDELSOHN, supra note 5, at 62,65; R. MENDELSOHN,
supra note 99, at 40; Koch-Weser, supra note 96, at 302-03; see S. SAGov, supra note 47, at 34.
124. Hearings, supra note 98, at 2140; R. MENDELSOHN, supra note 5, at 62, 65, 71.
125. N. COUSINS, supra note 103, at 115.
126. S. KLAW, supra note 102, at 23; Wartman, supra note 96, at 1358.
127. See, e.g., Niblack v. United States, 438 F. Supp. 383, 388 (D. Colo. 1977); Boyer v. Smith,
No. 80-12190-6, slip op. at 4 (C.P. Bucks County, Pa., Jan. 28, 1985), aff'd, 497 A.2d 646 (Pa. Super.
1985) (despite clear and strong warnings in the Physicians' Desk Reference, the physician prescribed
the drug); Trogun v. Fruchtman, 58 Wis. 2d 596,207 N.W.2d 297, 304 (1973); R. MENDELSOHN, supra
note 99, at 23; see also Besch, Informed Consent: A Patient's Right, NURSING OUTLOOK, January 1979,
at 32, 34.
The Physicians' Desk Reference ("PDR"), published by Litton Industries, is available to every
physician in the United States and is issued on an annual basis with supplements issued twice a year.
The PDR is basically an "encyclopedia of drugs widely used by physicians." Stevens v. Parke, Davis &
Co., 9 Cal. 3d 51, 507 P.2d 653, 662, 107 Cal. Rptr. 45, 48 (1973). Pharmaceuticals are listed
alphabetically by manufacturer and their products are listed alphabetically and medically by brand
name. The largest portion of the volume is the product-information section, which contains the
complete package insert issued by the manufacturer. Every physician has readily available, therefore, a
list of all of the risks associated with the drug reported by the manufacturer.
128. 1 PRESIDENT'S COMMISSION, supra note 96, at 83.
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overseeing the safety and efficacy of all drugs. 129 However, FDA enforce-
ment efforts appear to have little effect upon the process of prescribing
drugs. While the FDA has responsibility for regulating written drug label-
ing, it has no authority to oversee oral presentations given by detailmen to
prescribing physicians or to oversee the communications physicians make
to patients when prescribing drugs. Detailmen overpromote certain drugs
by, for example, emphasizing the benefits and ignoring or minimizing the
risks. 130 Physicians, in turn, rely on this information as an important source
of their knowledge about the drugs they prescribe. 131 FDA regulations do
little to control these overpromotional activities. 132 As can be expected, the
patient is the ultimate victim of industry overpromotion.
129. FDA regulations concerning new drugs (21 C.F.R § 310 (1985)) and the Federal Food, Drug,
and Cosmetic Act (21 U.S.C §§ 301-63 (1982)) are intended to control orto regulate only the actions of
the drug manufacturer. For example, FDA regulations list specific requirements for the warnings of
certain drugs, such as the oral contraceptive, and requires, among other things, the submission of a
sample batch to the Commissioner of the FDA. (21 C.F.R § 310.500 (1985)). The statute deals with the
application process for new drugs and requires that each application include: (1) full reports of
investigations that have been made to show whether the drug is safe and effective; (2) a full list of the
drug's ingredients; (3) a full description of the methods, facilities, and controls used for the manufac-
ture, processing, and packing of such drug; (4) a sample of such drug may be required; and (5) examples
of labeling proposed to be used for such drug. 21 U.S.C § 355(b)(1) (1982).
130. See supra note 109. An excellent example of overpromotion came in Stevens v. Parke, Davis
& Co., 9 Cal. 3d 51, 507 P.2d 653, 107 Cal. Rptr. 45 (1973). Despite directions from the FDA to include
a specified warning on the label of the drug chloromycetin, Parke, Davis minimized the risk in the
labeling language, while its salesmen continued a concentrated promotion of the drug. 507 P.2d at 656,
107 Cal. Rptr. at 47-48. Parke, Davis did not include the required warning in the 1962 PDR, its
detailmen personally visited doctors and urged them to use the drug without giving any verbal warnings
as to the risks (although brochures left with the physician apparently included written warnings), and
promotional "giveaways" (e.g., calendars and rulers) carrying the name chloromycetin carried no
warnings. Furthermore, "reminder ads" published in medical journals made no reference to the
possibility of harmful side effects. According to the FDA, however, Parke, Davis was required to
include warnings only in advertising material that stated specific recommendations as to proper uses
and dosage. 507 P.2d at 656 n.5., 107 Cal. Rptr. at 48 n.5. Thus, by this last directive the FDA arguably
aided in the overpromotion of the drug. Based on the finding of overpromotion, the court held for the
plaintiff. 507 P.2d at 663, 107 Cal. Rptr. at 55.
131. See Incollingo v. Ewing, 444 Pa. 263, 282 A.2d 206,216 (1971) (a physician prescribed the
extremely dangerous drug chloromycetin for even minor viral infections; he explained that he felt the
drug was safe because of the representations to that effect by the Parke, Davis detailmen); supra note
130.
132. The FDA, whose duty it is to keep unsafe drugs off the market, is handcuffed by the political
influence exerted by drug companies, and consequently, the protection afforded by the FDA is more
illusory than real. R. MENDELSOHN, supra note 5, at 73, 75-76. Often, once the FDA has discovered
that a drug has not met the required standards, the government is unable to remove the drug from the
market without long and tedious proceedings, and the drug will continue, often for years, to be
prescribed to an unknowing public. R. MENDELSOHN, supra note 99, at 33.
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B. Factors That Affect Patient Participation and Choice
1. Range of Treatment Alternatives
One of the most significant differences between consent to prescription
drugs and the typical informed consent situation involving surgery is the
availability of a greater number of treatment alternatives.133 A physician
may have a choice of eight or ten different drugs for a particular problem, 134
as well as nondrug alternatives that may prove safer, and yet just as
effective. 135 One physician has suggested that, as a general rule, physicians
lack confidence in nondrug alternatives to therapy and do not know enough
about nutrition, for example, to seriously consider it as an alternative. 136
In many, if not most, situations where a prescription drug provides only
one possible mode of therapy, an obvious alternative (although probably
not often enough recognized as such) is that of no treatment. 137 Once
patients have been apprised of the drug's risks, they might prefer no
treatment or a nondrug treatment such as bed rest. Failure to present
patients with the entire range of alternatives deprives them of the oppor-
tunity to make a meaningful choice, without which patients cannot exercise
their right of self-determination.
2. Patient Idiosyncrasies
Patients have their own unique medical and nonmedical preferences. 38
Although a patient's medical idiosyncrasies, such as allergies and past
medical history, play a role in both surgical and drug prescription settings,
both medical and nonmedical preferences of the patient are much more
important for drug prescriptions. These patient idiosyncrasies play a larger
133. 1 PRESIDENT'S COMMISSION, supra note 96, at 42; M. Belsky & L. Gross, supra note 116, at
144; B. Huttman, The Patient's Advocate 168 (1981); H. LENNARD, supra note 96, at 29, 104; R.
MENDELSOHN, supra note 5, at 58, 122-23, 128; R. MENDELSOHN, supra note 99, at 32, 38-39; T.
PRESTON, supra note 49, at 155; Andrews, supra note 55, at 178, 197; Besch, supra note 116, at 34;
Katz, supra note 22, at 147, 158; Rockwell, The Emotional Impact ofSurgery andthe Value ofInformed
Consent, 63 MED. CLINICS N. AM. 1341, 1348-49 (1979); Wartman, supra note 96, at 1359.
134. See Boyer v. Smith, 497 A.2d 646, 647 (Pa. Super. 1985) (court ignored fact that defendant
physician chose the most potent, and therefore, the most dangerous, drug with no discussion what-
soever with the patient about a host of available and safer alternatives); see also R. MENDELSOHN, supra
note 5, at 58.
135. R. MENDELSOHN, supra note 5, at 122-23. For example, while many oral contraceptives are
readily available, other, safer means of contraception that are equally as effective or nearly as effective
are also available. M. MiNTz, supra note 108, at 12-16.
136. R. MENDELSOHrN, supra note 99, at 46, 178.
137. See 2 PRESIDENT'S COMMISSION, supra note 5, at 167 table 5-4 (most physicians do not think
that informed consent includes informing about alternative treatments or no treatment); see also supra
note 116; Katz, supra note 22, at 157-58.
138. LeBlang, supra note 90, at285;Trichter& Lewis, supra note 54, at 164 (each patient unique);
supra note 93 and accompanying text; infra note 141 and accompanying text.
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role in prescribing drugs than they do in the more typical surgical setting,
mainly because of the complex and unique chemical reactions each individ-
ual has to prescription drugs. 139 In addition, the heightened concern about
nutrition and health, which often causes a person to stop smoking and to
avoid chemical additives in foods, may also lead that person to an aversion
to all drugs and to a preference for the nondrug, or least-potent-drug,
alternative. 140 By ignoring the patient's particular interests and concerns,
which might have a direct bearing on the drug therapy decision, the
physician ignores the individual being treated, and in effect treats only the
hypothetical "reasonable" or "average" person.
3. Risks Versus Benefits
Since all drugs are dangerous,141 a serious question arises whether the
total injuries and deaths caused by prescription drugs outweigh the cures
they effect. 142 As many as three of five drugs prescribed are estimated not to
139. 1 PRESIDENT'S COMMISSION, supra note 96, at 43; N. CousINs, HEALING H-ART 216 (1983); R.
MENDELSOHN, supra note 5, at 57-58; Brown, Supreme Court Judgment: Courts May Now Enforce
Stricter Standards of Disclosure on Doctors, 123 CAN. MED. Assoc. J. 1167, 1168 (1980); Cousins,
Potentiation and the Patient, 79 J. Mo. ST. MED. Assoc. 209,209 (1982); Dixon, supra note 55, at 62;
Malone, Informed Consent and Hospital Consent Forms: Paperchasing in a Video World, 61 J. URB. L.
105, 120-21 (1983); Rockwell, supra note 133, at 1349; Sieber, Informed Consent as Respectful
Communication, 72 OKLA. ST. MED. Assoc. J. 403, 403 (1979); Thomasma, Beyond Medical
Paternalism and Patient Autonomy: A Model of Physician Conscience for the Physician-Patient
Relationship, 98 ANNALS INTERNAL MED. 243, 246 (1983); Comment, supra note 47, at 199-200.
140. Information about side effects may have different significance to different patients. A high
incidence and a low magnitude or risk (high risk of a minor but ugly skin rash, for example) may be a
less acceptable risk to some patients than a low incidence and high magnitude of risk (remote risk of
stroke or fatal reaction). Moreover, both alternatives might be rejected by some patients in favor of no
treatment and its attendant risks. Courts, however, tend to look only to the incidence of risk. See, e.g.,
Watkins v. United States, 482 F. Supp. 1006, 1013 (M.D. Tenn. 1980) (court stated that physicians are
not required to warn of rare side effects, no matter what their magnitude); Harnish v. Children's Hosp.
Medical Center, 387 Mass. 152, 439 N.E.2d 240, 243 (1982); see also 2 PRESIDENT'S COMMISSION,
supra note 5, at 105 table 3.1; Andrews, supra note 55, at 197. The Canadian Supreme Court has
declared that material risks include those that are mere possibilities but of high magnitude. Reibl v.
Hughes, 1980 S.C.R. 880.
Material risks include: (1) minor risks with high incidence, (2) major risks with low incidence, and
(3) major risks with high incidence. See Koury v. Folio, 272 N.C. 366, 158 S.E.2d 548, 555 (1968)
(court held that parents must be given the opportunity of an informed election between exposing their
child to the risk of prolonged bronchitis and possible pneumonia on the one hand and incurring the risk
of total and permanent deafness of their child on the other).
141. Koch-Weser, supra note 96, at 303 (arguing that it is naive to think that drugs capable of
helping patients will not hurt somebody and that a completely safe drug is a pharmacological
absurdity); see Marsh v. Arnold, 446 S.W.2d 949, 952 (Tex. Civ. App. 1969) (any administration of
drugs by a physician involves risks); R. MENDELSOHN, supra note 5, at 72; R. MENDELSOHN, supra note
99, at 39 (there is no such thing as a safe drug; Eli Lilly himself once said that a drug without toxic
effects is no drug at all).
142. Hearings, supra note 98, at 2107; R. MENDELSOHN, supra note 5, at7, 105; R. MENDELSOHN,
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have the beneficial effect intended. 143 Even if this estimate is overstated, it
is clear that a large percentage of prescriptions are not effective. 14  In these
situations, the user has nonetheless been exposed to the drug's side effects.
Prescription drug therapy is less predictable than surgery, and the risk of
side effects is greater and more complex, than those usually associated with
surgery. 145 Taking several prescription drugs in combination enhances the
risk of side effects. 146 Risks are also enhanced when physicians, as they
often do, treat side effects from one drug by prescribing another drug. 147
Rarely can the physician or the patient feel comfortable about the efficacy
and safety of a drug because of the lack of adequate data about the
particular drug and the possibility of adverse reactions.148 This "uncer-
tainty," although indigenous to all of medical practice,149 pervades the
practice of prescribing drugs far more than it does surgical therapy. 150
An often overlooked aspect of prescription drug therapy is that the drug
affects not just the user but has a direct, physiological impact on other
persons. For example, a pregnant woman might want to weigh for herself
the benefits from her use of a particular drug against the risks the drug
presents to the fetus. 151
supra note 99, at 13; see also Calabrese v. Trenton State College, 162 N.J. Super. 145, 392 A.2d 600,
604 (1978) (plaintiff argued that the chance of rabies vaccine producing a dangerous side effect was
greater than the chance that plaintiff would contract rabies).
143. R. MENDELSOHN, supra note 5, at 58, 64.
144. S. KLAW, supra note 102, at 23-25; H. LENNARD, supra note 96, at 32.
145. 1 PRESIDENT'S COMMISSION, supra note 96, at 85-89; see also H. LENNARD, supra note 96, at
81; R. MENDELSOHN, supra note 5, at 70-71, 74, 75; L. TUSHNET, supra note 103, at 196 n.203.
146. See R. MENDELSOHN, supra note 99, at 41; S. SAGOV, supra note 47, at 103-04; L. TUSHNET,
supra note 103, at 204.
147. H. LENNARD, supra note 96, at 81; R. MENDELSOHN, supra note 99, at 31. In one case, for
example, the side effects from Thorazine are treated with artene, which in turn can cause a Thorazine
syndrome. R. MENDELSOHN, supra note 5, at 58; L. TUSHNET, supra note 103, at 209-10.
148. Hearings, supra note 98, at 2140; see Marsh v. Arnold, 446 S.W.2d 949, 952 (1969)
(physician testified that the benefits received from drugs outweigh the bad effects, but that any
administration of drugs is a precarious procedure and that the real dangers from the use of drugs are
unknown); Koch-Weser, supra note 96, at 303 (demand for completely safe drug is both naive and
absurd).
149. Physicians would be more cautious about claims to have found the answer to the treatment of
any disease if they developed an appreciation of medicine's vast ignorance. J. KATZ, supra note 5, at
182. Although certain drugs, such as anticoagulants, antibiotics, hypotensive agents, insulin, and
steroids have been available for 15 to 40 years, many of their true effects on patients and diseases are
unknown. Id. at 166; see also Watkins v. United States, 482 F. Supp. 1006, 1012 (M.D. Tenn. 1980)
(medicine is not an exact science).
150. J. KATZ, supra note 5, at xvii-xviii, 26, 46, 166. See generally I PRESIDENT'S COMMISSION,
supra note 96, at 30 n.48. For an interesting discussion of the uncertainty which physicians feel but won't
reveal to patients, see J. KATZ, supra note 5, at 170-71. For a discussion of the notion of "certainty" as a
goal of medical training, and the detrimental impact it has on the therapy and the choice of patients, see
id. at 183-87. See also S. KLAW, supra note 103, at 25-26; T. PRESTON, supra note 49, at 83-87.
151. See R. MENDELSOHN, supra note 99, at 39; R. MENDELSOHN, supra note 5, at 70-73,. 167-68;
L. TUSHNET, supra note 103, at 195. For another example of drugs exposing nonusers to risks, see
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The risk- benefits factor also requires the participation of the individual
patient in a manner that courts rarely recognize. The side effects from a
drug may be serious (a stroke) or minor (a skin rash). Thus, patients may
regard the magnitude of the possible side effects as very important to their
therapeutic choice. Similarly, a side effect may have a low (1 in 1,000,000,
for example) or high (1 in 100) chance of occurring. Consequently, patients
may also regard the incidence of the risk as important to their choice of
therapy. Courts tend to focus only on the incidence of the risks, assuming
that patients are concerned with serious side effects only when they have a
high probability of occurring. In so doing, courts fail to consider all of the
variables in this incidence-magnitude rubric. A particular patient's con-
cerns about the risk of side effects are likely to be more complex than courts
have recognized. A particular patient may be very concerned about a
serious side effect, even if the incidence is only 1 in 1000, if the benefits
from the drug are slight, such as relief from minor pain. Of course, the
greater the illness or pain, the more likely the patient may be to assume a
greater risk in order to obtain relief. The choice, however, belongs to the
patient, not to the physician. By failing to recognize all the variables and
combinations of the incidence-magnitude rubric, courts deprive patients of
the opportunity to make informed choices. 152
If courts examined closely the special factors that dominate prescription
drug therapy, they would not defer so readily to medical practice as the
standard for determining the existence and scope of the physician's duty to
inform in the prescription drug context. These same considerations would
cause courts to begin shaping an informed consent model that recognizes
the individual, idiosyncratic (not merely "reasonable") patient's need to
participate in prescription drug therapy. By moving to a subjective-patient
standard for determining proximate cause, courts would, for the first time in
the informed consent context, give full force and effect to the patient's
rights of self-determination and bodily integrity.
III. INFORMED CONSENT IN THE PRESCRIPTION DRUG
CONTEXT: PRESENT STATE OF THE LAW
Extreme deference to the medical profession is the most obvious aspect
of the judicial attitude toward informed consent in the prescription drug
context. While this deferential attitude pervades the entire field of informed
Plummer v. Abbott Labs., 568 F. Supp. 920 (D.R.I. 1983) (increased risk of cancer in daughters of
mothers who had taken DES); Kaiser v. SuburbanTransp. Sys., 65 Wn. 2d 461, 398 P.2d 14 (1965) (bus
driver lost consciousness at wheel because of side effects of a prescription drug, causing a collision and
injuries to passengers).
152. See supra note 140.
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consent, 153 it is striking against the background of the special factors
permeating prescription drug therapy. 154 According to several commen-
tators, courts seem to have little concern for preserving the rights of
patients and protecting them from drug abuses caused by the medical
profession and the drug industry. 155 Indeed, an analysis of the informed
consent standard applied in prescription drug cases indicates that courts
almost unanimously adopt a medical profession viewpoint rather than a
patient perspective. 156
Even though courts have generally refrained from asking the difficult
and essential questions about the scope of physicians' duty to communi-
cate, 157 the courts have not been injudicious or insensitive. Rather, the case
law demonstrates that deference to the medical profession, in conjunction
with the failure to recognize the special factors inherent in the prescription
of drugs, has caused courts to rely completely on the professional standard
to determine the presence of informed consent in the prescription drug
context. 158
In most prescription drug cases courts adopt and apply the medical-
community standard of disclosure with little or no stated rationale and with
rarely more than a reference to some unarticulated necessity to defer to the
judgment of the medical profession. 159 Although in adopting the objective-
patient model courts articulate more clearly the rationale for deferring to
the medical profession,160 the abrogation of patients' rights is essentially
the same. Both models ignore the needs and preferences of the particular
patient, although the reasonable-patient model may inadvertently protect
153. See supra notes 47-64 and accompanying text; infra note 160 and accompanying text.
154. See supra notes 91-132 and accompanying text.
155. J. KATZ, supra note 5, at58;R. MENDELSOHN, supranote5, at36, 119, 125-36;T. PRESTON,
supra note 49, at 112; S. SAGov, supra note 47, at 125.
156. See supra note 8.
157. See supra notes 51, 67-68, and accompanying text.
158. See supra note 8 and text accompanying note 156.
159. See, e.g., Watkins v. United States, 482 F. Supp. 1006, 1012 (M.D. Tenn. 1980) (court
observed that the law will not hold a physician guilty of negligence even if the physician's judgment
proved incorrect, unless it can be shown that the course chosen was clearly against the course
recognized as correct by the medical profession); Finley v. United States, 314 F. Supp. 909, 916 (N.D.
Ohio 1970) (court held that it could not formulate an independent judgment as to whether proper
medical standards require the giving of a cautionary instruction whenever a physician prescribes a
common medication with some known side effect); Carmichael v. Reitz, 17 Cal. App. 3d 977, 95 Cal.
Rptr. 381, 391-92 (1971) (existence and scope of physician's duty to inform should be established by
expert testimony of other physicians); Oakes v. Gilday, 351 A.2d 85, 89 (Del. Super. Ct. 1976) (court
required a showing of the applicable standard of the medical community in that locality or similar
localities); Pederson v. Dumouchel, 72 Wn. 2d 73, 79, 431 P.2d 973, 978 (1967) (physicians are
responsible in damages when they fail to exercise the degree of skill and care that is usually possessed
by the average member of the profession acting in the same or similar circumstances).
160. See supra notes 33-36 and accompanying text.
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the particular patient's needs and preferences if the information material to
the particular patient's choice happens to coincide with the information
material to the choice of the hypothetical "reasonable" patient. 161
A. Pennsylvania: A Case Study
One of the most expansive explanations for deferring to the medical
profession in the prescription drug context came in a recent Pennsylvania
trial court opinion, Boyer v. Smith. 162 Pennsylvania bases its informed
consent doctrine on a battery theory, 163 which the Boyer trial court believed
inapplicable in the prescription drug context. Nevertheless, the trial court's
opinion provides one of the clearest illustrations of both unwarranted
deference to the medical profession and a failure to consider any of the
factors unique to prescription drug therapy.
In Boyer, the jury found for defendant physician, who allegedly had
failed to advise plaintiff of the serious side effects associated with the use of
161. See supra note 32 and accompanying text.
162. Boyer v. Smith, No. 80-12190-6, slip op. (C.P. Bucks County, Pa., Jan. 28, 1985), aff'd, 497
A.2d 646 (Pa. Super. 1985).
163. The Pennsylvania Supreme Court adopted the doctrine of informed consent in 1966, basing its
theory on the fact that an operation without the patient's consent is a technical assault. Gray v.
Grunnagle, 423 Pa. 144, 223 A.2d 663,668-69 (1966). Gray involved a surgical procedure, which the
jury found was performed without the patient's consent. Gray, 223 A.2d at 664-65. In reversing the
trial court's judgment for defendant notwithstanding the verdict, the Pennsylvania Supreme Court failed
to set forth an express standard establishing the physician's duty to the patient. In a battery context, with
no issue of alternative treatment presented, the court apparently felt that the only standard needed was
one that ensures that the surgeon give the patient "a true understanding of the nature of the operation to
be performed." Gray, 223 A.2d at 674. The jury's only task in such a case is to determine whether the
plaintiff consented to the operation, or essentially to the operation, performed by the defendant. 223
A.2d at 674. Five years later the Superior Court of Pennsylvania, an intermediate appellate court, was
presented with a similar appeal involving the question whether defendant physician had informed
plaintiff adequately prior to performing a gastroscopic examination. Cooper v. Roberts, 220 Pa. Super.
260, 286 A.2d 647 (1971). The narrow factual issue raised by plaintiff was whether defendant had
informed plaintiff of the collateral risks, including perforation of her stomach, associated with the
procedure. Cooper, 286 A.2d at 648. Because Gray had recognized an individual's right to bodily
integrity, the superior court rejected use of the medical-community standard to determine whether
defendant had adequately informed plaintiff of collateral risks of the examination. Id. at 650. Without
other relevant precedent in Pennsylvania, the court looked to other jurisdictions and adopted a
reasonable patient standard. Id. However, because the gastroscopic examination in Cooper involved a
physical touching, the court in Cooper followed Gray by expressly recognizing that an operation
performed without an informed consent is a technical assault. Id. at 649. Later informed consent
decisions in Pennsylvania, including one prescription drug case, have refused to extend the doctrine of
informed consent to situations where no touching is involved. See Malloy v. Shanahan, 280 Pa. Super.
440, 421 A.2d 803,805 (1980); Boyer v. Smith, No. 80-12190-6, slip op. at 5 (C.P. Bucks County, Pa.,
Jan. 28, 1985), aff'd, 497 A.2d 646 (Pa. Super. 1985).
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the potent pain killer Butazolidin.164 Plaintiff had accompanied her hus-
band to his appointment with defendant, to whom she incidentally com-
plained about pain in her lower back and leg. 165 Defendant diagnosed the
condition as nerve root compression and prescribed both a ten-day supply
of Butazolidin and bed rest. 166 Defendant also advised her that Butazolidin
could cause oral and gastrointestinal ulcers. 167 However, he did not inform
her of other potential side effects, their probability of occurring, or of
alternative treatments, even though he was aware of Butazolidin's life-
threatening potential and of the existence of alternative less potent drugs. 168
Seven days after beginning the use of the drug, plaintiff suffered a severe
adverse reaction from which she almost died. 169
The trial court, apparently following Pennsylvania precedent, refused to
charge the jury on informed consent as a separate and distinct basis of
liability. 170 Nevertheless, the trial court went on to give an expansive
explanation for the court's deferential attitude to the medical profession in
the prescription drug context:
Unless the risk of serious side effects is substantial, drug treatment is not
ordinarily regarded as radical. It also differs significantly from surgical
procedures in its incidence and variety of applications. Regardless of the
degree of testing and governmental approval, it is well known that no drug is
entirely safe. . . . To require a physician to advise a patient of the warnings
and disclaimers of drug manufacturers would not serve the same beneficial
purpose as that of informed consent in a surgical situation. Confronted with
the dire consequences such as are enumerated in the Physicians' Desk
Reference, it would often be extremely difficult for a patient to make an
intelligent decision. A patient's ultimate reliance would still have to be placed
in a clinician's judgment to a far greater extent than in cases of surgery. 171
The trial court used the traditional malpractice standard to charge the
jury, asking thejury to determine whether the defendant physician failed to
act as a reasonable physician in the same circumstances. 172 On the basis of
164. Boyer v. Smith, No. 80-12190-6, slip op. at I (C.P. Bucks County, Pa., Jan. 28, 1985), aff'd,
497 A.2d 646 (Pa. Super. 1985).
165. Id.
166. Id.
167. Id. at 2.
168. Id.
169. Id.
170. Id. at 4; see supra note 163.
171. Boyer v. Smith, No. 80-12190-6, slip op. at 6-7 (C.P. Bucks County, Pa., Jan. 28, 1985),
aff'd, 497 A.2d 646 (Pa. Super. 1985).
172. Id. at 7. But see Cooper v. Roberts, 220 Pa. Super. 260, 286 A.2d 647, 650 (1971) (the court
refused to apply the reasonable physician standard to informed consent cases because the main issue
was whether the patient made an effective assent to treatment and not whether the physician conformed
to the accepted medical practice).
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this charge, the judge limited the plaintiff's argument to the jury, allowing
her to contend "that a reasonable practitioner would have disclosed the
remote possibility of a grave reaction to the taking of butazolidin." 173 In
refusing to charge the jury on informed consent as a separate theory of
liability,174 the trial court exhibited almost complete deference to the
medical profession. 175 The court's refusal to acknowledge any validity or
significance to a patient-oriented standard demonstrated a lack of recogni-
tion of the patient's need to participate in the drug prescribing process. Had
the trial court recognized the unique factors inherent in the prescription
drug context, many of which were directly involved in the case, it would not
have drawn the erroneous and unfounded conclusion that prescription drug
therapy requires less patient participation than do bodily invasive pro-
cedures, such as surgery.
The trial court either ignored or misapplied many of the special factors
inherent in prescription drug therapy. One factor implicated in Boyer was
the pervasive use of prescription drugs that is often caused by the need of
physicians to create certainty in the treatment setting. 176 If defendant
physician had not unilaterally decided to give plaintiff a particular quick
cure, and had he been more concerned with her participation in the
process, 177 he would likely have considered other alternatives, including a
more conservative therapy (bed rest) without any medication. 178
The factor of overprescribing 179 also played an important role in the case.
Defendant did not consider either a safer drug alternative or a nondrug
alternative. 180 In fact, defendant, like other physicians in the local medical
community, prescribed Butazolidin as a drug of first choice' 8' despite
strong warnings in the PDR to the contrary 82 and despite the fact that
plaintiff's condition was not included in the list of indicated uses for
Butazolidin when defendant prescribed it. 183
173. Boyer v. Smith, No. 80-12190-6, slip op. at 7 (C.P. Bucks County, Pa., Jan. 28, 1985), aff'd,
497 A.2d 646 (Pa. Super. 1985).
174. Id. at 2.
175. Id. at 6.
176. For a discussion of the need for certainty, see supra notes 101, 150 and accompanying text. For
a discussion of the tendency to overprescribe in general, see supra notes 102-15 and accompanying text.
177. See Reproduced Record at 355a-58a, Boyer. For a discussion of patient idiosyncrasies in
general, see supra notes 138-40 and accompanying text.
178. See Reproduced Record at 148a-49a, Boyer.
179. For a discussion of overprescribing in general, see supra notes 102-15 and accompanying
text.
180. Reproduced Record at 145a-46a, 242a, Boyer.
181. Id. at 155a-56a, 246a-47a, 358a-59a. Defendant testified that he was aware that the PDR
stated that Butazolidin should not be considered as a drug of "first choice." Id. at 152a.
182. Id. at 151a-52a. For an explanation of the role the PDR plays in the prescription process, see
supra note 127.
183. Reproduced Record at 196a, Boyer.
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Overprescribing also relates to, and is in fact manifested in, another
important factor present in Boyer. At the time defendant prescribed
Butazolidin for plaintiff, numerous drugs were available as alternatives, 184
all of which were less potent and therefore less likely to cause dangerous
side effects. 185 The defendant did not mention to the plaintiff any of the
alternatives to Butazolidin, drug or nondrug. 186 The trial court failed to
mention alternatives in its opinion, despite the fact that defendant admitted
that he had known at the time that eight to ten alternative drugs were
available, and despite the fact that expert testimony established that bed
rest, without drug therapy, was a viable alternative in plaintiff's case. 187
The trial court barely acknowledged the risk-benefit factor by recogniz-
ing that all drugs have some danger inherent in their use. 188 The court
implictly recognized the risk-benefit factor in allowing the plaintiff to
argue to the jury that a reasonable physician would have disclosed to
plaintiff the "remote possibility" 189 of a grave risk inherent in the use of
Butazolidin. Nevertheless, by emphasizing the low incidence of the risk,
the court effectively played down the seriousness of the side effects; the
failure to disclose the seriousness of the side effects denied the plaintiff the
opportunity to make an informed choice. 190 Additionally, by not charging
the jury on informed consent as a separate theory of recovery, and by
applying the professional standard of the reasonable medical practitioner,
the court forced thejury to ignore the preference plaintiff might have had as
a result of the incidence of the risk and the magnitude of the side effect.
184. For a discussion of alternatives generally see supra 133-37 and accompanying text.
185. Reproduced Record at 242a, Boyer. Bed rest was also a viable alternative therapy for plaintiff.
Id. at 197a. Of all the alternatives for treatment for plaintiff at that time, Butazolidin was the most potent
and the most likely to cause life-threatening side effects. Id. at 242a. Butazolidin is the trademark of
Geigy Pharmaceuticals, a Division of the Ciba Geigy Corporation, for phenylbutazone, a nonsteroidal,
antiarthritic, anti-inflammatory agent. PHYSICIANS DESK REFERENCE 878 (32d ed. 1978) [hereinafter
cited as PDR]. The PDR warns that Butazolidin should never be administered casually and in bold print
instructs the physician to thoroughly read information provided before prescribing the drug. Id. Among
the adverse reactions listed in the PDR are liver dysfunction, fatal blood dyscrasias, including aplastic
anemia, peptic ulceration, and gastrointestinal bleeding. Id. Further, the PDR warns that in individuals
forty and over there is an increase in the possibility of adverse reactions. Id. at 879.
186. Boyer v. Smith, No. 80-12190-6, slip op. at 2 (C.P. Bucks County, Pa., Jan. 28, 1985), aff'd,
497 A.2d 646 (Pa. Super. 1985).
187. Reproduced Record at 148a, Boyer.
188. Boyer v. Smith, No. 80-12190-6, slip op. at 2 (C.P. Bucks County, Pa., Jan. 28, 1985), aff'd,
497 A.2d 646 (Pa. Super. 1985).
189. Id. at 7. The court interpreted the jury's verdict as establishing that the reasonable orthopedist
in the same circumstances as the defendant physician would not have made known the drug's extremely
toxic, but unusual side effects. Id.
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Plaintiff's condition was not life-threatening and did not demand immedi-
ate, high-powered therapy.191 Under the circumstances, she might well
have chosen a less potent pain killer, with less risk of serious side effects,
despite the fact that the incidence of grave risk from Butazolidin was low.
In its memorandum opinion, the trial court did not indicate whether
plaintiff's idiosyncrasies played any role in its decision. It appears, how-
ever, that the court failed to consider this factor in formulating the dis-
closure standard. Defendant physician admitted that he did not take the
plaintiff's medical history, other than a brief history of the origin of the
pain. 192 Yet the PDR193 indicates that no prescription of Butazolidin should
be written without first taking a detailed history of the patient.194 The court
made no mention of the physician's failure to follow this procedure.
Moreover, both the court and the defendant failed to consider whether
plaintiff, if given information about an alternative treatment, might have
had some personal, or idiosyncratic, preferences about what risks of side
effects she was willing to accept in order to relieve her pain. 195 Plaintiff,
however, was not given a choice.
Although prescription drug use requires constant monitoring, the court
apparently ignored the role monitoring played in the patient's situation. 196
The then-current edition of the PDR stated that any patient under treatment
with Butazolidin "should remain constantly under the close supervision of
the physician. "197 The PDR also recommended that any prescription of the
drug should be for a one-week period.198 Yet defendant gave plaintiff a ten-
day prescription, with no instructions to report back to him sooner than
seven to ten days. 199 These instuctions did not reflect the fact that plaintiff,
at fifty-five years-of-age, was in the higher risk category of users, to whom
the PDR suggests that physicians give careful instructions. 200
191. Plaintiff was suffering from sciatica, which caused leg and back pains. Boyer v. Smith, No.
80-12190-6, slip op. at 1 (C.P. Bucks County, Pa., Jan. 28, 1985), aff'd, 497 A.2d 646 (Pa, Super.
1985). Plaintiff was not working; taking care of Mr. Boyer was her sole responsibility. Record On
Appeal at 357a, Boyer. Defendant prescribed Butazolidin because he assumed she was working and he
considered her condition acute. Id. at 107a. Nevertheless, defendant had over 15 drugs to chose from,
many of which had less risk of side effects. Id.
192. Reproduced Record at 135a, Boyer.
193. See supra note 127.
194. Reproduced Record at 98a, 147a-48a, Boyer; PDR, supra note 185, at 878.
195. See supra notes 138-53 and accompanying text.
196. For a discussion of the need for monitoring in general, seesupra notes 116-21 and accompany-
ing text.
197. Reproduced Record at 147a, 151a, Boyer; PDR, supra note 185, at 878.
198. Reproduced Record at 148a, Boyer; PDR supra note 185, at 878.
199. Reproduced Record at 159a-60a, 377a, Boyer.
200. Id. at 150a-51a, 196a-97a, 377a; PDR, supra note 185, at 879. Patients over 40 years-of-age
presented increased risks, with special attention required when patients were 60 or older. Id.
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One last aspect of the uniqueness of prescription drug therapy that the
court apparently overlooked is the limited pharmacological knowledge of
prescribing physicians. 201 The defendant testified that he understood the
pharmacology of Butazolidin, which presumbably resulted in his failure to
consult the PDR before prescribing the drug for plaintiff.20 2 At that time,
however, defendant did not even have a copy of the PDR in his office. 203
Despite defendant's professed knowledge of the pharmacology of
Butazolidin, he prescribed it as a drug of first choice against a strong
warning to the contrary in the PDR;2° 4 he gave it to plaintiff, who at the time
was fifty-five, well above the age at which the PDR indicated that the drug,
already dangerous, becomes much more toxic;20 5 he prescribed the drug
with virtually no instructions, whereas the PDR warns that to avoid life-
threatening adverse reactions, it is essential that the physician give careful
instructions to the individual patient;20 6 and he prescribed the drug, as
apparently did many of his local peers in his locality, for a condition for
which the PDR indicates the drug is not intended. 207
Before adopting a medical-community perspective over a patient-
oriented disclosure standard, courts should consider the type of facts and
circumstances present in Boyer: (1) technical information concerning the
prescribed drug was available in the PDR, the content of which is regulated
by the FDA (although provided to the PDR's publisher by the drug
manufacturers); 20 8 (2) the technical information contained a warning in
clear language about the possibility of serious side effects under certain
circumstances; 20 9 (3) the patient appeared to fall within those circum-
stances; and (4) the medical condition was neither an emergency nor life-
threatening. 210
These facts and circumstances dictate that the court should have se-
riously questioned the appropriateness of a deferential standard of dis-
closure. 211 Unless courts require physicians to consider such facts and
201. For a discussion of physicians' lack of pharmacological knowledge in general, see supra notes
122-32 and accompanying text.
202. Reproduced Record at 152a, Boyer.
203. Id. at 147a.
204. Id. at 152a; see PDR, supra note 185, at 878.
205. Reproduced Record at 150a-51a, 196a-97a, Boyer.
206. Id. at 151a; PDR, supra note 185, at 878.
207. Reproduced Record at 196a, Boyer; PDR, supra note 185, at 878.
208. See supra notes 129-32 and accompanying text.
209. Reproduced Record at 98a, 103a-04a, Boyer.
210. See supra note 191.
211. The Boyer court explained its decision as follows:
To require a physician to advise a patient of the warnings and disclaimers of drug manufacturers
would not serve the same beneficial purpose as that of informed consent in a surgical situation.
Confronted with the dire consequences such as are enumerated in the Physicians' Desk Reference
it would often be extremely difficult for a patient to make an intelligent decision. A patient's
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circumstances and to communicate them to the patient, the patient's rights
of self-determination and bodily integrity have no force and effect.
B. Other Jurisdictions
Boyer graphically demonstrates judicial deference to the medical profes-
sion and disregard for the special factors pertaining to prescription drug
therapy. Other jurisdictions have adopted similar attitudes. Some jurisdic-
tions, for example, have demonstrated a desire to maintain the medical-
community standard by overlooking, and even rationalizing, physicians'
failure to use the PDR to maintain their knowledge of the risks associated
with drug therapy.212 Wisconsin courts seem to exhibit a similar attitude.
For example, in Trogun v. Fruchtman,2 13 plaintiff contracted hepatitis from
the use of the drug isoniazid hydrazate ("INH"), which had been pre-
scribed for an inactive case of tuberculosis. 214 Plaintiff's condition fell into
the least serious category of inactive cases. 215 The court held that because
physicians in plaintiff's locality were not aware of the risk of contracting
hepatitis from the INH treatment, 216 defendant was not negligent in failing
to warn plaintiff of this risk.217 Yet the PDR published one year before
defendant prescribed the drug for plaintiff indicated that hepatitis was a risk
inherent in the use of the drug.2
18
In obvious deference to the medical-community standard, the Trogun
court minimized the PDR information about the risk of hepatitis in two
ways. It played down the risk of hepatitis identified in the PDR by over-
emphasizing PDR language identifying hepatitis as one of the risks that had
ultimate reliance would still have to be placed in a clinician's judgment to a far greater extent than
in cases of surgery.
Boyer v. Smith, No. 80-12190-6, slip op. at 6-7 (C.P. Bucks County, Pa., Jan. 28, 1985), aff'd, 497
A.2d 646 (Pa. Super. 1985).
There is no basis for the assertion that warnings of drug reactions do not serve the same purpose as do
warnings of adverse consequences of surgery. That it would be difficult for a patient to make an
intelligent decision in a particular case is not a valid reason to deprive patients of all choice, either in that
case or in all cases. In light of the particular, but probably not unique, circumstances of her situation,
one suspects that had the plaintiff in Boyer been given some choice, she probably would have chosen an
alternative treatment. Whether she ultimately would have relied on the defendant's judgment and
consented to use of Butazolidin cannot be known with any assurance because her doctor never discussed
risks or alternatives with her.
212. For a discussion of PDR use in general, see supra notes 122-32 and accompanying text.
213. 58 Wis. 2d 596, 207 N.W.2d 297 (1973).
214. Trogun, 207 N.W.2d at 299.
215. Id. at 304. Plaintiff had a "primary" case, the least serious of the four categories of inactive
tuberculosis. Id.
216. This finding, reached on appeal, was based on the testimony of medical experts at trial.
Trogun, 207 N.W.2d at 310.
217. Id. at 315.
218. Id. at 304 (quoting PDR, supra note 185 (1967 ed.)).
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"occasionally been reported." 219 Nowhere in the opinion does the court
state what probability of risk it interprets "occasionally" to mean. The
court, however, does make clear that it focused only on what it saw as a low
incidence of risk and ignored any consideration of the magnitude of the side
effect. The court continued to overemphasize the PDR language by quoting
in italics a sentence from the PDR not italicized therein: "Side effects are
infrequently encountered and are rarely serious." 220 Contrary to the court's
implied finding, hepatitis is very serious; even if hepatitis occurs infre-
quently, the PDR gives adequate notice of the severe risks of hepatitis. 221
By minimizing the effect of the PDR language, the court gave decisive
weight to the testimony of physicians that they were not aware of the risk of
hepatitis as a side effect of the drug INH.222
Courts have routinely failed to take into consideration the interrela-
tionship between the incidence and the magnitude of the side effect, as they
relate to the patient's underlying condition. 223 In this respect, courts tend to
overlook or ignore particular concerns and preferences, even idio-
syncrasies, that patients may have regarding the risks they are willing to
accept. 224 A New Jersey case, Calabrese v. Trenton State College,225
illustrates the point. Plaintiff argued, unsuccessfully, that the court should
have considered that his risk of contracting rabies was slight under the
circumstances, but the risk of side effects from the rabies treatment was
substantial, especially considering the seriousness of the side effects. 226 In
fact, plaintiff suffered brain damage as a result of the treatment. 227 The
Calabrese court, relying on standard medical judgment, held that plaintiff
need not have been informed of the risks. According to the court, the
adequacy of disclosure to the patient must be measured by the medical-
219. See id.
220. Id.
221. For a discussion of the relationship of the incidence and magnitude of the risks of all
alternatives, including that of no treatment, in conjunction with the risks associated with the patient's
underlying condition, see supra notes 140-52 and accompanying text.
222. Trogun, 207 N.W.2d at 304, 310. Another example of a court engaging in similar rationaliz-
ing came in Niblack v. United States, 438 F. Supp. 383 (D. Colo. 1977). In Niblack, the court lumped
together the risk of aseptic necrosis, a relatively serious condition, with every other side effect,
including minor ones, without considering the incidence and magnitude relationships and the impact
disclosure of these relationships would have had on plaintiff's decision. Id. at 384 n.2, 388-89.
223. See supra notes 140-52 and accompanying text.
224. See supra notes 138-40 and accompanying text.
225. 162 N.J. Super. 145, 392 A.2d 600 (1978).
226. Plaintiff had presented the argument that "the remoteness of the danger of rabies, when
considered in the light of the possible adverse side effects associated with the anti-rabies vaccine, makes
the prevention of rabies a greater hazard than the hazard presented by an untreated dog bite victim."
Calabrese, 392 A.2d at 604.
227. Plaintiff suffered "chronic severe organic brain damage secondary to [the] rabies vaccine."
Id. at 603.
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community standard because no lay jury can be expected to reach a
conclusion on such a technical matter unaided by such testimony. For
example, it may well be that medical practice regards the risk material to
the case as being so statistically remote that, when measured by the gravity
of harm to be expected from lack of such treatment, disclosure thereof is
normally not made.228
Reliance on professional medical judgment focused the Calabrese
court's attention solely on probability ("statistically remote"), 229 causing
the court to ignore the severity of the side effect. Calabrese demonstrates
two aspects of a court's attitude about the patient's role in the decisionmak-
ing process. First, the court was unwilling to consider any particular
concerns or preferences the patient may have had about accepting the
risks.2 0 The court's failure to recognize the key role played by the factors
inherent in prescription drug therapy, such as the incidence-magnitude
rubric,231 led the court to endorse standard medical judgment. This reliance
on medical judgment compounded the problem because physicians reach
such judgments by failing to recognize the same special factors and their
importance to particular patients. Thus, courts and physicians deprive
patients of the right to make fundamental choices concerning their own
bodies.232
Second, the Calabrese court relied on the argument that a lay jury cannot
understand technical matters without the aid of expert medical testi-
mony.2 33 This argument demonstrates confusion of the need for expert
medical testimony regarding the existence of particular risks (not all cases
require such testimony) with the relatively easy question of whether the
patient received and understood information pertinent to that patient's
decision. By combining the two issues under the guise of technicalities
requiring expert medical opinion, the court is again led to the adoption of
the medical-community standard.
The nearly universal application of the medical-community model in
prescription drug cases deprives patients of the opportunity to make
fundamental choices concerning their own bodies. For the judiciary to give
full force and effect to the patient's rights of self-determination and bodily
integrity, courts must fashion a new informed consent model that focuses
on the patient's individual decisionmaking process.
228. Calabrese, 392 A.2d at 606.
229. Id.
230. Id. at 604.
231. See supra notes 140-52 and accompanying text.
232. See supra notes 15-21 and accompanying text.
233. Calabrese, 392 A.2d at 606.
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IV. PROTECTING THE PATIENT'S RIGHT TO CHOOSE: A
PROPOSED DUTY/DISCLOSURE SCHEME
A. The Foundation
In determining the scope of the disclosure duty in prescription drug
cases, courts must recognize that there are special factors that bear directly
and indirectly upon the needs and concerns of all the parties. Without
recognizing the importance of these factors, courts cannot give protection
to the basic right of self-determination and bodily integrity of patients
undergoing drug therapy.234
Courts must also examine their willingness to accept entrenched medical
attitudes as the basis for all rights and liabilities inherent in the doctrine of
informed consent. Physicians prescribe drugs without adequately consid-
ering the special factors pertaining to patients' circumstances and con-
cerns. In addition, physicians are unwilling to trust patients to know their
own needs. 235 Given the attitude of most physicians, the doctrine of
informed consent will be, at best, merely one canon in a code of profes-
sional conduct, with no effective legal basis, unless courts are willing to
intervene. Courts must recognize that they, better than the medical profes-
sion, can formulate legal standards for professional medical conduct.2 36
Finally, courts must focus on the essential purpose of the doctrine of
informed consent. The doctrine is based on the fundamental notion of
individual autonomy. 237 Implicit in the language of individual autonomy is
the protection of the individual's dignitary interest. 238 In prescription drug
234. See supra notes 15-21 and accompanying text: see also Canterbury v. Spence, 464 F.2d 772,
781 (D.C. Cir.), cert. denied, 409 U.S. 1064 (1972); Cooper v. Roberts, 220 Pa. Super. 260, 286 A.2d
647, 649 (1971).
235. See J. KATZ, supra note 5, at 85-86.
236. Canterbury v. Spence, 464 F.2d 772, 784 (D.C. Cir.) ("Respect for the patient's right of self-
determination on particular therapy demands a standard set by law for physicians rather than one which
physicians may or may not impose upon themselves."), cert. denied, 409 U.S. 1064 (1972).
237. The root premise is the concept, fundamental in American jurisprudence, that "[e]very
human being of adult years and sound mind has a right to determine what shall be done with his own
body." Schloendorff v. Society of N.Y. Hosp., 211 N.Y. 125, 105 N.E. 92, 93 (1914). True consent
requires that the patient make an informed choice, which includes the opportunity to evaluate
knowledgeably the options available and their risks. Canterbury v. Spence, 464 F.2d 772, 780 (D.C.
Cir.), cert. denied, 409 U.S. 1064 (1972); see supra notes 15-21 and accompanying text.
238. See supra note 46. Courts also should consider that patients have certain contractual rights.
The surgical context is an area basically governed by contractual concepts, under which the surgeon
must operate in accordance with the agreement made between the parties. Cooper v. Roberts, 220 Pa.
Super. 260, 286 A.2d 647, 651 (1971). Consent for the operation or treatment arises from the contract
between the surgeon and the patient, with consent limited to what the parties understood was to be done.
Cooper, 286 A.2d at 65 1. A patient's agreement to a procedure, including prescription drugs, cannot be
considered informed consent unless the patient understands all reasonable alternatives and risks. To
understand the extent of the contract between the parties, the patient must have this knowledge.
Apparently, courts find that patients waive their right to be informed in prescription drug therapy about
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cases, courts have upheld the autonomy of physicians by adopting the
medical-community standard and in the process have overlooked the dig-
nity and autonomy of the individual patient. 239 Even if those courts applied
the alternative objective-patient model, they would still fall short of pro-
tecting the rights of particular patients. Through closer scrutiny in the
prescription drug context of the duty, scope of duty, and proximate cause
considerations that underlie the doctrine of informed consent, courts would
recognize the need to set standards that reflect the particular patient's
perspective.
B. A Patient-Oriented Standard: The Need for Subjectivity
An objective-patient model cannot be applied successfully to prescrip-
tion drug cases. Courts reject the subjective-patient model in favor of an
objective-patient model because they fear that a subjective standard would
impose an unrealistic burden on physicians. 240 Requiring physicians to
communicate with their patients is neither unrealistic nor unfair.241 The
"objective" standard, however, does not depend on meaningful communi-
cation between physician and patient, but on a nondescript process that
ultimately relies completely on medical opinion in lieu of patient participa-
tion.
As the court in Canterbury v. Spence noted, the objective approach calls
for physicians, based on their medical training and experience, to "sense
how the average, reasonable patient expectably would react." '242 This
standard does not impose any legal obligation on the physician to commu-
nicate with the patient. Rather, the physician need only reach a unilateral
decision by "sensing" how the patient feels.243 Furthermore, the physi-
cian's preferred drug will prevail because medical training and experience
teach the physician not to communicate with a fully participating pa-
tient.244 Relying on a physician's ability to sense what the particular patient
wants often leads to miscommunication. In Boyer v. Smith, 245 the physician
serious, but statistically remote risks, or about alternative drug or nondrug treatment.
239. See supra notes 8, 15-21 and accompanying text.
240. See, e.g., Canterbury v. Spence, 464 F.2d 772,787 (D.C. Cir.) (the physician can never know
exactly what the patient would consider important to his decision), cert. denied, 409 U.S. 1064 (1972);
Cooper v. Roberts, 220 Pa. Super. 260,286 A.2d 647,650-51 (1971) (reasonable patient standard gives
maximum effect to the patient's right to be the arbiter of the medical treatment he will undergo without
requiring the physician to be a mindreader).
241. See supra notes 82-85 and accompanying text.
242. 464 F.2d 772, 787 (D.C. Cir.), cert. denied, 409 U.S. 1064 (1972).
243. Id. at 787.
244. J. KAaz, supra note 5, at 39-40.
245. No. 80-12109-6, slip op. (C.P. Bucks County, Pa., Jan. 28, 1985), aff'd, 497 A.2d 646 (Pa.
Super. 1985).
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developed his inaccurate impressions because of inadequate communica-
tion with the patient. 246 The court should not have held that such impres-
sions created an adequate basis for prescribing Butazolidin for the patient.
C. Disclosure Scheme
1. Affirmative Duty to Communicate
Any reasonable standard of disclosure must be based on an affirmative
duty to communicate fully. 247 In order to delineate the requirements of ade-
quate communication, it is important to recognize that a nondescript sensing
of how "the average, reasonable patient expectably would react" 248 cannot
substitute for thorough and meaningful communication between physician
and patient. 249 Reading the mind of the patient in order to determine the
information pertinent to the patient's decision is not an adequate standard for
the burden of communication. 250 What is needed is a straightforward
articulation of a standard of meaningful communication that incorporates
the full disclosure that the objective model optimally would require. 251 The
246. See supra notes 164-69, 192-95 and accompanying text.
247. This approach presupposes that courts do not indulge in any presumptions, as some courts
have, that the medical practitioners have properly discharged their duty. See Watkins v. United States,
482 F. Supp. 1006 (M.D. Tenn. 1980); Finley v. United States, 314 F. Supp. 905 (N.D. Ohio 1970).
Such an approach represents unwarranted deference to the medical profession. See supra notes 47-95
and accompanying text. There is no articulated or obvious reason for this deference. See Watkins, 482 F.
Supp. at 1012; Finley, 314 F. Supp. at 911. See generally J. KATZ, supra note 5, at 1-29. This
presumption adds to plaintiff's burden of persuasion, if not burden of production, and eases defendant
physician's corresponding burdens. The presumption is ultimately another example of the failure of the
courts to recognize the basic and fundamental right of self-determintion of each individual. For
discussion of physicians' affirmative duty to invite their patients to think with them and to work
collaboratively toward a decision, see J. Katz, supra note 5, at 59, 133, 144-47, 211.
248. See Canterbury, 464 F.2d at 787.
249. In fairness to Judge Robinson, author of the court's opinion in Canterbury, it appears that he
did have in mind some notion of communication, for he recognized that a physician could learn enough
about the particular patient to determine what information would be material to that patient's decision.
464 F.2d at 787. Canterbury, however, sets forth a narrowly limited duty to communicate. The
physician must communicate, in effect, only with the average, reasonable patient, and not in any
meaningful sense with the particular patient. Id. at 787. Further, the physician need make little effort to
ensure that the patient understands the communication, and in fact fulfills the duty merely by conveying
information without engaging the patient in any meaningful dialogue. Id. at 780 n. 15. Sensing what
information would be material to the average patient's decision is a poor substitute for asking the
particular patient what information is important to his or her decision. See Scott v. Bradford, 606 P.2d
554, 559 (Okla. 1979).
250. See supra note 76.
251. See Canterbury, 464 F.2d at 787 (most optimal standard from patient perspective is to require
disclosure of potential risk whenever the particular patient would deem it significant in giving an
informed consent). Under the duty that objective-patient courts settle upon, the physician is bound to
disclose what information reasonable persons would consider material to their decision whether to
undergo drug therapy. This does not require the physician to be a mindreader or require disclosure of
every risk. Cooper v. Roberts, 220 Pa. Super. 260, 286 A.2d 647, 650 (1971). The Cooper duty is to
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communication must be based on the right of self-determination and bodily
integrity of particular patients without undermining those rights by falling
back onto a reasonable-patient standard.252
Thorough, two-way communication benefits both physician and pa-
tient. The physician is assured of fair treatment and the communication
protects patients' rights of self-determination and bodily integrity. More-
over, thorough communication almost certainly results in less patient
resentment253 and better healing.254
disclose "all those facts, risks, and alternatives that a reasonable man in the situation which the
physician knows or should have known to be the plaintiff's would deem significant in making a decision
to undergo the recommended treatment." Cooper, 286 A.2d at 650. Nevertheless, the Cooper
communication requirement poses as much difficulty as the Canterbury requirement. See supra notes
34, 249. Many, or perhaps even most, physicians do not as a rule make this full disclosure before
prescribing drugs, and most patients accept the physician's judgment that a prescription drug is the
appropriate therapy. See supra notes 5-6 and accompanying text. Consequently, the physician most
likely perceives the reasonable patient as passive and unquestioning. By adopting the objective
standard, a court reinforces the practice of limited, noncommunicative disclosure by an autonomous
physician to a passive patient. See, e.g., Boyer v. Smith, No. 80-12109-6, slip op. at 6 (C.P. Bucks
County, Pa., Jan. 28, 1985), aff'd, 497 A.2d 646 (Pa. Super. 1985). Just as physicians have a need to
take action, and writing a prescription satisfies this need, patients also have a need to have action taken
by the physician because they want something in return for the fee being paid. Receiving a prescription
satisfies this need. Consequently, not only must physicians learn to ask questions, but they must be
persuaded to use that skill and to communicate more readily. Of course, a plaintiff's verdict in a
malpractice lawsuit might begin to educate the physician about the reasonable person concept. But
courts have a responsibility to articulate the physician's duty in easily understandable language before
the risk materializes. Communicating with a particular patient is easier for, and fairer to, the physician
than having to make a legal determination of what constitutes the reasonable person in a particular
medical context.
Although both Canterbury and Cooper recognized the need for physicians to communicate fully with
the particular patient, both courts settled for a communication and disclosure standard that defers to
professional medical judgment.
252. See J. KArz, supra note 5, at 75-76. As Professor Katz stated:
The whole point of the inquiry [is] to safeguard the right of individual choice, even where it may
appear idiosyncratic. Although law generally does not protect a person's right to be unreasonable
and requires reasonably prudent conduct where injury to another may occur, it remains ambiguous
about the extent to which prudence can be legally enforced where the potential injury is largely
confined to the individual decision maker. For example, courts have split on the question of
whether. . . an adult patient may be compelled to undergo unwanted blood transfusions.
Id. at 76 (footnotes omitted).
In Canterbury, Judge Robinson recognized the need to move toward a subjective standard, yet chose
not to do so for fear of unduly burdening the physician. 464 R2d at 785. Further, he reintroduced the
community-medical standard by declaring that when medical judgment enters the picture, prevailing
medical practice must be given its just due. Id. However, he failed to set out the meaning or limits of
"just due." "[I]f the grand rhetoric of self-determination is to have meaning, framing the question in
terms of the reasonable person grossly and unnecessarily substitutes judicial paternalism at a critically
wrong point." J KATz, supra note 5, at 77; see also Scott v. Bradford, 606 P.2d 554 (Okla. 1979).
253. It appears that less patient resentment would reduce, perhaps significantly, the number of
medical malpractice suits filed. N. CousiNs, supra note 139, at 162-63 ; J. KATZ, supra note 5, at
209-10; E. MIscHLal, supra note 120, at 106, 117; T. PRESTOMN, supra note 49, at 190-91; S. SAOOv,
supra note 47, at 125; J. STEwn, supra note 99, at 98-99; see also J. KAtz, supra note 5, at 114
409
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2. The Communication Process
In any case where the physician determines that a prescription drug is a
possible, recommended, or preferred mode of treatment, the legal standard
should require the physician to determine the spectrum of prescription
drugs that could be used. In many cases, numerous drugs could be
employed within a range going from barely effective (but safe) to extremely
effective (but relatively dangerous). 255 The physician must also identify,
where possible, the least potent and least dangerous as well as the most
potent and most dangerous of the available drugs, and determine the risks
and hazards of each by consulting the PDR or other reliable and readily
available source of such information. 256
In addition to considering alternative drugs, any meaningful consent to
prescription drug therapy presupposes that the patient understands the
alternatives to drug therapy, including diet, surgery, or even no treatment.
Thus, the physician must determine alternative treatment (and nontreat-
ment) methods as well as the significant risks associated with those alter-
natives. 257
(subsequent disagreements between physician and patient will be less disturbing).
Even if informed consent liability makes a physician act only for self-preservation, the final result
will be the same as if the physician's actions were motivated by a concern for patient welfare. The
patient benefits, through better health care, realistic expectations of the treatment, and increased
confidence and trust in the physician; the physician benefits through fewer lawsuits. See generally
Comment, Informed Consent in Medical Malpractice, 55 CAL. L. REv. 1396 (1967); Meisel, The
Expansion of Liability For Medical Accidents: From Negligence to Strict Liability by Way ofInformed
Consent, 56 NEB. L. REv. 51 (1977). "Defensive medicine," however, does have its drawbacks, and is
not an acceptable substitute for open, meaningful communication. Defensive medicine results in
overtreating and overtesting, both at considerable cost to the patient. "Since doctors who are sued tend
to have had poor relationships with their patients from the beginning, it seems that . . . a close,
personal, and friendly doctor-patient relationship is the best preventive measure." S. SAGov, supra note
47, at 124-25.
254. Patients who are not adequately informed prior to a procedure or a treatment tend to do poorly
afterwards when compared to patients who received adequate information. See generally McHugh,
Christman & Johnson, Preparatory Information: What Helps and Why, 1982 AM. J. NURSING 780.
Patients who are better informed have a realistic idea of what to expect and are not surprised orconfused
by an unexpected reaction to the drug. See 1 PRESIDENT'S COMMISSION, supra note 96, at 153f; M.
BELSKY & L. GROSS, supra note 116, at 139; E. MISCHLER, supra note 120, at 128 n.81; T. PRESTON,
supra note 49, at 24; S. SAGov, supra note 47, at xx.
255. See supra notes 133-37 and accompanying text.
256. See supra notes 122-32 and accompanying text. For example, in Boyer, the prescribing
physician did identify the most potent drug, but failed to go further and share that information with the
patient. Boyer v. Smith, No. 80-12190-6, slip op. at 5 (C.P. Bucks County, Pa., Jan. 28, 1985), aff'd,
497 A.2d 646 (Pa. Super. 1985). Although the defendant physician in Boyer did not consult the PDR
prior to prescribing Butazolidin for plaintiff, id. at 6, it is likely there are cases where the physician
knows a particular drug, as well as its alternatives and the side effects of each, thoroughly enough to be
able to proceed without consulting thePDR. Such a situation is probably more rare, however, than most
physicians would admit.
257. See supra notes 122-32, 140-52 and accompanying text.
410
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Before communicating medical and nonmedical choices to patients,
physicians have a duty to consider both the standard medical history and
medical idiosyncrasies (for example allergies, age, and sex) and to consider
the nonmedical history, background, and idiosyncrasies of each patient (for
example the patient's personal health habits including whether the patient
is a smoker, drinker, or drug user).258 Nonmedical idiosyncrasies have an
important bearing on the individual's treatment preferences. Some patients
have a high level of curiosity and special concern about health. This
concern often prompts these patients to stop smoking, to avoid or reduce
the consumption of alcohol, and to monitor diet very carefully as to salt,
sugar, fat, chemical additives, and caffeine. Such patients might well have
some thoughts and feelings about prescription drug therapy that the physi-
cian ought to take into consideration during any discussion of alternatives
and risks.259
Having considered both the prescription drug and nondrug therapeutic
alternatives, including no present treatment, and having become familiar
with the particular patient's idiosyncrasies, both medical and nonmedical,
the physician is in a position to disclose all the treatment alternatives and
the risks associated with them26° that might be significant to the particular
patient.261 Based on the patient's medical history and particular conerns,
habits, and idiosyncrasies, the physician should enumerate all of the
258. See supra notes 138-40 and accompanying text; 1 PRsmiDENT's CoMMISSION, supra note 96, at
38-39, 71, 154; J. KATZ, supra note 5, at 78, 82-83.
259. The study of nutrition seems to be of little importance in the medical school curriculum. See
N. CousiNs, supra note 103, at 114-15, 117. However, enough is known about the relationship between
diet and health that physicians have dietary choices available as alternatives to drug therapy in a variety
of situations, id. at 114, including diet and exercise as an alternative treatment for diabetes and handling
stress.
260. 1 PREsIDENT's COMMIssION, supra note 96, at 76-77; N. CousmNs, supra note 103, at 134-35
(increasing technology pushing the physician further away from the patient); J. KATz, supra note 5, at
75 (mere risk disclosure inadequate); S. SAoov, supra riote 47, at xxii, 23, 135 (use accessible,
everyday language); Andrews, supra note 55, at 188-89, 191-94,217. See generally Scott v. Bradford,
606 P.2d 554 (Okla. 1979); Holt v. Nelson, 11 Wn. App. 230, 523 P.2d 211 (1974); Trichter & Lewis,
supra note 54, at 11.
261. See supra notes 249-51 and accompanying text. The test for whether the physician has
disclosed all the necessary facts, risks, and alternatives necessary to the reasonable plaintiff's decision,
the so-called "materiality" test, is sometimes stated in terms of what information the plaintiff would
deem to be "significant" in making the consent. See Cooper v. Roberts, 220 Pa. Super. 260, 286 A.2d
647, 650 (1971). In Canterbury, Judge Robinson seems to prefer the word "material." 464 F2d 772,
787 (D.C. Cir.), cert. denied, 409 U.S. 1064 (1972). However, the courts in Cooper and Canterbury
have in mind the same test. The materiality test, which they apply to the reasonable patient, can apply
more readily to a particular patient, but with additional emphasis on "alternatives," including no
treatment. See supra notes 237-38; see also Cooper, 286 A.2d at 651. If there is a significant difference
between the Cooper and Canterbury application of the materiality test it is that Canterbury seems to
focus more on "risks" with little or no reference to additional "facts" and "alternatives." Canterbury,
464 F.2d at 779. On the other hand, Cooper focuses more on additional facts and alternatives. 286 A.2d
at 650.
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alternatives that would likely affect the patient's choice of therapy. There
are, of course, exceptional circumstances in which the physician would be
justified in withholding certain information from particular patients. These
exceptions, or "privileges," have been clearly defined in numerous court
decisions. 262 Finally, the physician must determine whether the patient is
able to make an informed choice. To meet this responsibility, the physician
need only inquire, by means of a brief dialogue, 263 whether the patient
sufficiently understands each alternative and its attendant risks.
3. Elements of a Claim
To claim lack of informed consent in a prescription drug case, a plaintiff
should have to establish the same elements required for other claims of lack
of informed consent-duty, breach, causation (both in fact and proximate),
and damages. In a prescription drug case, however, particular elements
ought to be given special emphasis because of the unique nature of
prescription drug therapy.264
The obligation of the physician is to communicate and not merely to
disclose risks. 265 The duty to communicate in a meaningful fashion, taking
into consideration the unique aspects of prescription drug therapy, 266
262. The most commonly used exceptions to disclosure include: (1) nondisclosure of a risk which
was not reasonably foreseeable and not inherent in the procedure; (2) the therapeutic privilege (full
disclosure would be detrimental to the patient's best interests); (3) nondisclosure of commonly known
risks that the patient will be presumed to already know; (4) no disclosure is required where the patient
explicitly requests to be told no information; and (5) a physician need not disclose the various
alternatives and risks in an emergency situation. E.g., Holt v. Nelson, 11 Wn. App. 230, 240-41, 523
P.2d 211, 218-19 (1974).
263. Physicians sometimes argue that an "active practice" precludes meaningful dialogue with
patients, and courts sometimes seem to accept that argument. See Kaiser v. Suburban Transp. Sys., 65
Wn.2d 461,469,398 P.2d 14, 19 (1965). But see Katz, supra note 22, at 159-60 (physicians do not have
to "sense" or "second guess" how the patient will react; instead physicians should explore what
questions need further explanation); Trichter & Lewis, supra note 54, at 165-66 (enhanced
informational flow substantially increases the physician's opportunities to learn a patient's history,
physical condition, and mental state).
264. See supra notes 94-152 and accompanying text.
265. J. KArz, supra note 5, at 23 (only the individual knows).
When patients have a relationship based upon confidence and honesty with their physicians, and
when, through this increased communication, patients have a better understanding of the treatment,
studies have shown patients do better. See generally McHugh, supra note 254; Meisel, supra note 253.
The patient has realistic expectations of the treatment's effects and won't be shocked by an unknown
side effect. Further, by increasing the quality of communication the number of malpractice suits
brought should decline. See supra notes 253-54. At a decreased risk of being sued, physicians would be
encouraged to treat high-risk patients and to practice less defensive medicine. Lack of information is
often a precipitating factor in treatment refusals by patients. Patients who discover that certain
procedures are potentially very risky refuse treatment until reasonable justification and more informa-
tion is provided. I PRESIDENT'S COMMISSION, supra note 96, at 80.
266. See supra notes 94-152 and accompanying text.
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ultimately rests on the rights of bodily integrity and self-determination of
the patient as an individual, not as a reasonable or average person. 267
A breach of the prescribing physician's duty consists of any failure to
communicate with the patient in a meaningful fashion.268 Meaningful
communication requires the physician to discuss with the patient each of
the following considerations: all prescription drug alternatives; all other
alternative therapies, including no treatment; the risks of each alternative;
and the particular patient's idiosyncratic needs, desires, and preferences,
both medical and nonmedical. A failure to communicate regarding any one
of the required considerations would constitute a breach of the prescribing
physician's duty.
The causation element of a plaintiff's claim has two parts: causation in
fact and proximate causation. Causation in fact is in reality medical
causation, established by proof that the drug in fact caused the plaintiff's
injury.269
267. See supra notes 15-21 and accompanying text.
268. See supra notes 34, 64-69, 72-74, 85-86 and accompanying text.
On the other hand, the community-medical standard requires the use of expert testimony to establish
what would constitute a breach of the duty to communicate. The physician is liable only for violating
this medical-community standard. See, e.g., Watkins v. United States, 482 F. Supp. 1006 (M.D. Tenn.
1980) (community medical standard plus a presumption of due care on the part of the physician); Finley
v. United States, 314 F. Supp. 905 (N.D. Ohio 1970) (diagnosis is technical and specialized subject
matter on which expert testimony is necessary to establish standards of proper conduct, but expert
testimony is not necessary when physician's negligence has been so gross it requires only common
knowledge to understand); Calabrese v. Trenton State College, 162 N.J. Super. 145, 392 A.2d 600
(1978) (adequacy of disclosure determined by expert testimony; the plaintiff also employs expert
testimony); Koury v. Follo, 272 N.C. 366, 158 S.E.2d 548 (1968); Kaiser v. Suburban Transp. Sys., 65
Wn. 2d 461,464, 398 P.2d 14, 16 (1965). With the introduction of the objective "reasonable" patient
standard, expert testimony as to the prevailing community medical standard is no longer necessary or
controlling. See, e.g., Canterbury v. Spence, 464 F2d 772 (D.C. Cir.), cert. denied, 409 U.S. 1064
(1972); Cobbs v. Grant, 8 Cal. 3d 229, 104 Cal. Rptr. 505, 502 P.2d 1 (1972); Hamilton v. Hardy, 37
Colo. App. 375,549 P.2d 1099 (1976); Wilkinson v. Vesey, 110 R.I. 606,295 A.2d 676 (1972); Hunter
v. Brown, 4 Wn. App. 899, 484 P.2d 162 (1971); Trogun v. Fruchtman, 58 Wis. 2d 596, 207 N.W.2d
297 (1973). However, expert testimony may be used to establish the prevailing community-medical
standard, which the defendant physician may raise as a defense. See, e.g., Niblack v. United States, 438
F. Supp. 383 (D. Colo. 1977) (physician may raise community-medical standard and therapeutic
privilege as a defense); Hunter v. Brown, 4 Wn. App. at 907, 484 P.2d at 1166-67 (the medical standard
might be relevant and material in persuading the trier of facts that the surgeon disclosed all facts that his
patient should know for purposes of informed consent, and such evidence should be weighed as any
other evidence and be judged by "reasonable man" standards of conduct).
With the subjective-patient standard, the prima facie case does not require expert testimony; nor
should such testimony be available as a defense. But see Klink v. G. D. Searle & Co., 26 Wn. App. 951,
614 P.2d 701 (1980); Holt v. Nelson, 11 Wn. App. 230, 523 P.2d 211 (1974).
269. Typically, this proof requires expert medical testimony. See Finley v. United States, 314 F.
Supp. 905, 910 (N.D. Ohio 1970) (diagnosis is a technical and specialized subject matter on which
expert testimony is necessary to establish standards of proper conduct); Calabrese v. Trenton State
College, 162 N.J. Super. 145, 392 A.2d 600 (1978) (the plaintiff must use expert testimony to establish
that the treatment used had certain risks).
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The proximate cause element of a plaintiff's claim relates directly to the
validity of the consent. The question is whether plaintiff would have
consented to the drug therapy had adequate disclosure and discussion been
provided by the prescribing physician. 270 Aside from the issue of whether it
is the particular plaintiff or the reasonable person who would have con-
sented, 27' use of the subjective patient (particular plaintiff) standard raises
the additional question of the admissibility of plaintiff's hindsight testi-
mony.2 72 If courts exclude plaintiff's testimony on this point, little evi-
dence would be available to the plaintiff for proving proximate cause. 273
270. See, e.g., Canterbury, 464 F.2d at 790 (court found a causal connection existed only when
disclosure of significant risks incidental to treatment would have resulted in a decision against treatment
by a prudent person in the patient's position); McPherson v. Ellis, 305 N.C. 266,272,287 S.E.2d 892,
896 (1982) (court stated that subjective standard required the jury to determine whether, if informed,
this particular patient would have foregone treatment); Holt v. Nelson, 11 Wn. App. 230, 236, 523 P.2d
211, 216 (1974) (causal connection exists between physician's failure to inform the patient of risks
involved and injury suffered by the plaintiff only when disclosure of significant risks incidental to
treatment would have resulted in a decision against treatment, with the patient's testimony being
relevant, but not controlling); see also Niblack v. United States, 438 F. Supp. 383, 389 (D. Colo. 1977)
(physician's failure to warn patient of possible side effects of proposed treatment was not the proximate
cause of injuries suffered by the patient because of these side effects, where even if the patient had been
adequately informed of the risk of these side effects, he would not reasonably have rejected the
treatment); Sharpe v. Pugh, 270 N.C. 598, 155 S.E.2d 108, 113 (1967) (subjective standard); Kaiser v.
Suburban Transp. Sys., 65 Wn. 2d 461, 465, 398 P.2d 14, 16 (1965) (discussion of intervening acts);
Trogun v. Fruchtman, 58 Wis. 2d 596, 207 N.W.2d 297, 315 (1973) (objective standard).
271. See supra notes 10, 22, 30-45, 67-76, and accompanying text.
272. It is obviously self-serving for plaintiff to state, after suffering an injury caused by a
prescription drug, that had there been adequate communication by the physician, plaintiff would not
have taken the drug. Canterbury v. Spence, 464 F.2d 772, 790 (D.C. Cir.) (plaintiff's testimony hardly
represents more than a guess, perhaps tinged by the circumstances that the uncommunicated hazard had
materialized), cert. denied, 409 U.S. 1064 (1972); Scaria v. St. Paul Fire & Marine Ins., 68 Wis. 2d 1,
227 N.W.2d 647, 654 (1975) (hindsight testimony places the physician in jeopardy of the patient's
bitterness and places the fact finder in the position of deciding whether a speculative answer to a
hypothetical question is to be credited); see also Niblack v. United States, 438 F. Supp. 383, 389 (D.
Colo. 1977); Cobbs v. Grant, 8 Cal. 3d 229, 104 Cal. Rptr. 505, 502 P.2d 1, 11 (1972); Hamilton v.
Hardy, 37 Colo. App. 375, 549 P.2d 1099, 1105 (1976) (self-serving, speculative, and subjective).
Plaintiff's self-serving testimony would also seem to have no relevance in a case where an objective,
reasonable patient standard was being used. Nonetheless, some courts do allow it i0 the prescription
drug context, even where an objective standard is used. See, e.g., Canterbury, 464 F.2d at 791.
Although the relevance objection is not present where the particular patient standard is used (see Scott
v. Bradford, 606 P.2d 554, 558-59 (Okla. 1979)), the objection to the testimony as speculation and
conjecture is still valid.
273. It is conceivable that objective testimony, either by plaintiff, or by persons who know
plaintiff, concerning plaintiff's health habits and concerns, or about plaintiff's minor condition (e.g.,
mild pain) might constitute a sufficient basis upon which the jury could conclude that the particular
patient would not have consented had adequate communication been made. This situation, however.
would appear to be the exception. In most cases it seems likely that plaintiff could offer little or no
admissible evidence on this point.
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Courts could solve this evidentiary dilemma by creating a presumption
that the particular plaintiff would not have consented had adequate com-
munication been made. 274 This presumption would protect plaintiff's
dignitary interest,275 which is the essential component of plaintiff's rights
of self-determination and bodily integrity. Courts should view the dignitary
interest as the paramount interest to be protected. 276 Creating the presump-
tion that plaintiff would not have consented but for the physician's failure to
communicate adequately appears, on its face, to prejudice the interest of
the defendant physician. However, the courts must begin to focus not on the
privileges of physicians, but on the rights of patients, which courts have
recognized only by lip service277 and have, in fact, left unprotected. 278 In
fairness to physicians, the presumption ought to be rebuttable. Although
274. The presumption would arise only after plaintiff had introduced evidence from which a jury
could reasonably find that the communication was so inadequate as to constitute a breach of the
physician's duty. See supra notes 81-85 and accompanying text; infra note 281 and accompanying text.
A similar presumption exists in the securities fraud context, where the plaintiff need not subjectively
prove the causation element, but rather a "presumption" of reliance may be raised. See Blackie v.
Barrack, 524 F.2d 891, 906 n.22 (9th Cir. 1975). The Blackie court concluded that causation is
adequately established by proof of purchase and of the materiality of misrepresentations, without direct
proof of reliance. 524 F.2d at 906. The misrepresentations are material in the sense that a reasonable
investor might have considered them important in decisionmaking. Once causation has been established
by this presumption, the burden shifts to the defendant to disprove the prima faie case of causation in
one of two ways: (I) by disproving materiality or (2) by proving that an individual purchased despite
knowledge of misrepresentation, or that the purchase still would have been made despite disclosure. Id.
An alternative solution to this evidentiary dilemma in the prescription drug context is the use of
expert (psychiatrist or psychologist) testimony that given plaintiff's psychological makeup, plaintiff
would not have consented to using the drug had adequate communication been made. Even assuming
that expert opinion is admissible to predict future or hypothetical behavior, which seems a questionable
assumption, the procedure would add a cumbersome and expensive element to plaintiff's claim without
protecting plaintiff's rights of self-determination and bodily integrity. See supra notes 15-21, 46 and
accompanying text.
275. Plaintiff's dignitary interest is clearly not protected if an objective, reasonable-patient
standard is applied to the causation test. See Scott v. Bradford, 606 P.2d 554, 557-59 (Okla. 1979); see
also supra note 46 and accompanying text. Moreover, the dignitary interest is also not protected even if
a subjective standard is used since there appears to be an insurmountable evidentiary barrier to proving
an element of plaintiff's claim. See supra note 273.
276. See supra notes 15-21, 46 and accompanying text.
277. J. KATz, supra note 5, at 77-80, 83, 84. There is in this society public policy designed to
encourage doctors to render aid and assistance, and to protect them when doing so, as evidenced by the
"Good Samaritan Statutes." A general policy to promote individual health, however, can hardly be the
basis for overriding the traditional common law rights of self-determination and bodily integrity. See
supra notes 15-21 and accompanying text. These individual rights, given essential protection by the
doctrine of informed consent, do not compete with or contradict the policy of promoting individual
health. Informed consent, and the accompanying physician-patient communication, may in fact
promote rather than interfere with better individual health care. See supra note 254.
278. See supra notes 47-93, 151-233 and accompanying text. Use of the proximate cause
presumption has the additional benefit of preserving the integrity of the rules of evidence. See supra
notes 272-73 and accompanying text.
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rebutting the presumption would not be easy, 279 if the patient can prove
every other element of the claim, a rebuttable presumption of proximate
cause does not create a basic unfairness.2 80
The patient ought to be required to prove physical or emotional injury in
order to recover on an informed consent claim.28' Since courts can ade-
quately protect the patient's dignitary interest by the rebuttable presump-
tion of no consent, continuing to require plaintiffs to prove actual damages
does not significantly prejudice any interest of the patient. Moreover, the
actual damage requirement should protect physicians from patient harass-
ment. Elimination of the plaintiffs' burden to prove actual damages might
result in a dramatic increase in frivolous claims.
V. CONCLUSION
Undoubtedly, contemporary medical technology, and especially pre-
scription drugs, provide extensive benefits to patients. However, these
benefits are offset, both qualitatively and quantitatively, by the risk of
dangerous side effects created by that same technology. 282 One can under-
stand why medical practitioners have a preference for the technological
solution to medical problems. 283 Prescribing a drug, for example, focuses
the patient on a specific, medical concern and creates an expectation that as
a matter of course the illness will be cured. 284 The physician can thereby
avoid having to interact with the patient as a person and as a consequence
spend less time with each patient in the "active practice." This approach to
medicine, and specifically to prescription drug therapy, does not ensure
279. See supra note 262.
280. If plaintiff's dignitary interest is to be given adequate protection, the presumption probably
ought to be rebuttable in only the exceptional case. Defendants ought to be able to rebut the presumption
where they can clearly prove that the patient would still have consented after being fully informed. See
supra note 274. The patient could certainly waive any rights to be informed, for example, and
presumably proof thereof would rebut the presumption. See supra note 262. In any event, any
unfairness to the physician is far outweighed by the gross infringement of the patient's fundamental
rights of self-determination and bodily integrity that now occurs under the present standards of
informed consent. See supra notes 86-90 and accompanying text.
281. Arguably, to give full recognition to the patient's dignitary interest, the patient ought to be
able to recover without proof of any physical or emotional injury. See J. KATz, supra note 5, at 79. A
recovery in such a case, however, would be unfairly punitive.
282. See supra notes 102-05, 122-32, 141-52 and accompanying text.
283. See N. CousINs, supra note 103, at 134-35 (increasing technology pushing the physician
further away from the patient); see also infra note 284 and accompanying text.
284. This expectation arises as a result of the patient's strong need for treatment. See Hearings,
supra note 98, at 1303. In addition, writing a prescription is often an "easy-out" for a physician. See
Wartman, supra note 96 (prescriptions often result from the assumption that it is a concrete, definable
action that should be the natural outcome of a visit to a physician).
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happier patients, better healing, better medicine in general, or adequate
protection of a patient's rights of self-determination and bodily integrity.285
The counterpart to technological medicine lies essentially in better
communication by physicians. 286 Such communication will not take place,
however, until courts adopt a subjective model of informed consent. It has
been too easy for physicians to think of treatment solely in terms of the
disease and selecting the best remedy based on incomplete medical
criteria.
Courts have confused the question whether a patient or a jury can grasp
technicalities of medical science with the separate question whether the
treatment decision should be made by the physician and patient on the basis
of factors that physicians must get from the patient, not from their medical
training and background. This confusion results in protection for physi-
cians and their expertise through the medical-community standard. Little
incentive is left for physicians to change their practice in a manner that
would give protection to patients' rights of self-determination and bodily
integrity.287
Only courts can recognize the rights of individual patients and give
meaning to those rights by fashioning a clear, unequivocal, and fair duty of
informed consent.288 Courts must set forth the physician's duty to obtain an
informed consent in the prescription drug context by focusing on the
particular patient with regard to both the scope of the duty and proximate
cause. Until courts place physicians under a duty to inform, judicial
opinions will continue to perpetuate medical autonomy at the expense of
individual liberty. Without judicial intervention, patients' rights of self-
determination and bodily integrity, as well as the intangible dignitary
interest, will continue to be little more than empty promises.
285. See supra notes 15-21, 46, 96-115, 138-40 and accompanying text; see also 2 PRESIDENT'S
CoMMissioN, supra note 96, at 86 table 2-23 (only 35% of the public is very satisfied with their doctor);
M. BELSKY & L. GROSS, supra note 116, at 139; J. KArz, supra note 5, at 209, 210, 212; E. MISCHLFR,
supra note 120, at 106, 128; S. SAGOV, supra note 47, at 125; L STEiN, supra note 99, at 98-99.
286. J. KA-z, supra note 5, at 82-84; R. MENDELSOHN, supra note 5, at 78; T. PPEsTON, supra note
49, at 155; R. MENDELSOHN, supra note 99, at 173-83.
287. N. CousIs, supra note 103, at 111; J. KATz, supra note 5, at 28-29; R. MENDELSOHN, supra
note 99, at 173-83; see supra notes 15-21 and accompanying text.
288. J. KATz, supra note 5, at 62, 77-78, 84.

